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SUMMARY: 
 
Urodele amphibians have the remarkable ability to re-grow lost body parts. This 
regenerative response after injury in urodeles involves dedifferentiation of fully 
differentiated cells into proliferative cells. One well-studied example of this is the 
dedifferentiation of multinucleated muscle cells into mononucleate cells resembling 
their precursors, the myoblasts. To form these mononucleate cells the differentiated 
myotubes in vivo must re-enter and complete the cell cycle; they again proliferate and 
produce progeny. A key question is what factors induce the myotubes to re-enter the 
cell cycle and proliferate. Early events of cell cycle re-entry can be studied in the A1 cell 
line, a myogenic cell line isolated from the Notophthalmus viridescens hindlimb, which 
traverses cell cycle until G2 in response to serum. In particular, it was found that 
thrombin cleavage induces a factor in serum of all animals tested so far to promote S 
phase re-entry in A1 myotubes. 
We have used this S phase re-entry of the A1 cell line to purify the serum activity and 
developed a 5-step purification protocol that enriches the activity almost 2 000 fold over 
the starting material, or 40 000 fold over serum. To conveniently produce and test 
potential candidates for their ability to induce S phase re-entry in A1 myotubes, we also 
developed an overexpression- and purification system for emerging candidates. 
Candidates were then tested for this activity with or without prior incubation with 
thrombin. 
We identified Bmp proteins as the first pure molecules that were found in fractions 
across the purification of the activity and that could also induce cell cycle re-entry in a 
dose-dependent manner when recombinantly added to the A1 myotubes. Furthermore, 
this response could be blocked in a dose-dependent manner by the known bmp-
inhibitor noggin. Finally, we showed that inhibition of Bmp signaling in vivo causes 
defects in axolotl tail regeneration. 
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I.  Introduction 
 
A. Regeneration 
1. Regeneration in the animal kingdom 
 
Regeneration is defined as a biological term meaning the growth anew of lost tissue or 
destroyed parts or organs. This also states one of the fundamental differences between 
regeneration and development. Whereas in development structures are formed for the first 
time, regeneration is the process of re-forming some structure that has existed before and that 
quite often is still partially present. The fascinating ability to regenerate missing body 
structures or organs can be found throughout the animal kingdom in various degrees of 
complexity. Some rather simple organisms such as the hydra or the planarian Schmidtea 
mediterranea can even undergo bidirectional regeneration; they can regenerate a fully 
functional animal from both body fragments after transsection. Whereas the ability to 
regenerate substantial parts of the body is widespread amongst metazoans, only very few 
vertebrates possess this ability (Brockes, 1997) and regeneration in vertebrates is 
unidirectional. The true masters among regenerating vertebrates are urodele amphibians, but 
other animals can regenerate specific parts of their body as well. Teleost fish for example can 
regenerate their fins and especially the zebrafish Danio rerio has lately emerged as a widely 
used model organism to study regenerative phenomena (Akimenko et al., 2003). However, 
the vertebrate champions of regeneration are the urodele amphibians, and especially two 
species, the red-spotted newt Notophthalmus viridescens (Fig. I-1) and the axolotl 
Ambystoma mexicanum are widely used in experimental studies. 
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Figure I-1: Notophthalmus viridescens, the red spotted newt (Brockes and Kumar, 2005).  
The upper panel shows an adult aquatic newt, the lower panel a red eft, the juvenile terrestrial form. 
2. Regeneration in urodeles 
 
Urodele amphibians are often used as model organisms in regenerative studies because they 
are the only organisms that are evolutionary close to mammals with such astonishing 
regenerative capacities. In addition, in case of the axolotl, they can easily be bred in the lab. 
These traits make them excellent model organisms to study regeneration. The most 
commonly studied regenerative phenomenon is limb regeneration, but urodeles can also 
regenerate their tail including the spinal cord, their retina, lens, heart ventricle and jaw 
(Brockes and Kumar, 2002; Straube et al., 2004). Despite being evolutionarily very close, 
axolotls and newts can regenerate different parts of their bodies in different ways, for 
example after lentectomy, only the newt can regenerate the lens from the dorsal iris (see Fig. 
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I-8), whereas the axolotl cannot grow a new lens. However, there are also striking similarities 
in how they regenerate other structures, for example their limbs. 
 
Figure I-2: Regenerating newt limbs (modified from (Goss, 1969)). 
Notophthalmus viridescens limbs were amputated above (left panel) or below (right panel) the elbow and 
photographs taken before as well as 7, 21, 25, 28, 32, 42 and 70 days after amputation. Note the appearance of 
the blastema “cap” within the first weeks of regeneration. Structures distal to the amputation plane are 
regenerated as an exact copy of the missing structure. 
Epimorphic amphibian limb regeneration, the regenerative process in which cellular 
proliferation leads to the outgrowth of a new structure (Morgan, 1901) is critically dependent 
on the formation of a mesenchymal growth zone, the blastema (Wallace, 1981). The major 
hallmark of urodele limb regeneration is thus the formation of a blastema. Immediately after 
limb injury or amputation, epithelial cells begin to crawl over the wound and form the wound 
epidermis. Within one day after wounding the blastema, a mesenchymal growth zone, begins 
to form from the dedifferentiating cells in the stump tissues and continues to expand. Within 
weeks after amputation, the blastema is readily visible on the amputated limbs (Fig. I-2). The 
morphology in the limb blastema is quite different from that of the limb stump, as the 
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blastema is an unstructured cell mass and specific tissues such as bone and muscle are still 
recognizable in the limb stump. Many analyses showed that a major contributor to the 
blastema is the skeletal muscle (Casimir et al., 1988; Echeverri et al., 2001; Hay, 1959; 
Lentz, 1969; Steen, 1968; Thornton, 1938). 
An important aspect of regeneration that readily occurs in urodeles but that seems to be 
absent in mammals is the dedifferentiation of fully differentiated cells. Dedifferentiation is 
the loss of specific cellular features acquired by differentiation and the subsequent re-gaining 
of the ability to proliferate. Since dedifferentiation can occur in urodele regeneration but not 
in its mammalian counterpart, it is thought to be one of the mechanisms generating 
differences in regenerative capacity between urodeles and mammals. Re-activation of 
resident stem cells also is thought to play an important role in regeneration, but only recently 
Morrison et al. managed to show convincingly that they participate in amphibian limb 
regeneration (Morrison et al., 2006). It now seems clear that dedifferentiation as well as stem 
cell activation plays a role in regeneration but to what extent this is the case across species 
and tissues remains to be elucidated. My thesis work was concerned with the 
dedifferentiation aspect of regeneration, and especially with the dedifferentiation of skeletal 
muscle cells, so in the following I will focus on this topic. First I will briefly discuss 
differentiation and dedifferentiation of the skeletal muscle, then focus on the cell cycle re-
entry aspect of the dedifferentiation response, before having a closer look at serum that 
harbors a molecule initiating the cell cycle re-entry in cultured newt myotubes. The 
thrombin-induced activation of this molecule and the efforts undertaken to identify this 
molecule will be discussed in the last part of this introduction. The goal of this thesis was to 
identify this molecule initiating the cell cycle re-entry in A1 myotubes. 
 
B. Skeletal muscle 
1. Differentiation 
 
The differentiated muscle has been a good model cell type to study the withdrawal from the 
cell cycle and the maintenance of the differentiated state (Lassar et al., 1994). Expression of 
myogenic regulators plays an important role in switching from proliferative growth and cell 
 12 
division to activation of the differentiation program. These myogenic regulators are 
antagonized by growth factors and oncogenes in the precursor cells and the tight and correct 
regulation of this agonist – antagonist interaction is crucial for cellular differentiation.  
Proliferation in cells of other lineages can also be blocked by some myogenic factors of the 
MyoD family when overexpressed in high amounts, causing a growth arrest not related to 
their effect on differentiation. This suggests that the cellular molecular machinery involved in 
withdrawing cells from the cell cycle is conserved among different cell types, the cell cycle 
block being achieved by the same downstream molecules responsive to mediators from 
different lineages (such as MyoD family members) (Olson, 1992). One protein that is 
generally considered to be one of the key players in cell cycle withdrawal and in maintenance 
of the differentiated state is the tumor suppressor retinoblastoma (pRb) protein. In normal 
progression through the cell cycle, pRb needs to be phosphorylated by cyclin dependent 
kinases such as CDK 4/6 and this can be inhibited by cyclin-dependent kinase inhibitors such 
as p21 or p16 (Lukas et al., 1995). Gu et al. demonstrated that inhibition of pRb- activity by 
various means such as phosphorylation, genetic modification or the presence of SV40 T 
antigen inhibits differentiation of myotubes. They also show that MyoD and pRb directly 
bind each other and that this binding is competed by the SV40 T antigen (Gu et al., 1993). 
The critical role of pRb will be discussed in more detail in the chapter on cell cycle re-entry 
below. 
 
2. Dedifferentiation 
 
A prerequisite for regeneration and thus dedifferentiation to occur in vivo is local wounding. 
This local wound is often implicated as the trigger of a signaling cascade that in addition to 
leading to wound healing, hemostasis and tissue repair also initiates the regenerative response 
(Godwin and Brockes, 2006). This hints at the possibility of a master regulatory gene that is 
turned on in response to wounding, but no such gene has been identified to date. Skeletal 
muscle cell dedifferentiation can be separated into three distinct processes, (1) phenotypic 
dedifferentiation, (2) fragmentation or cellularization of the multinucleated muscle cells into 
mononucleated cells, and (3) cell division, which involves cell cycle re-entry and 
reorganization of centriolar material (Fig. I-3) (Duckmanton et al., 2005). For cells to fully 
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dedifferentiate all of these processes have to be initiated and many researchers have 
postulated the existence of a master regulatory protein. Of these processes, fragmentation and 
cell cycle re-entry have been studied most extensively and will briefly be discussed below, 
whereas the loss of differentiation-specific genes, for example muscle-specific myosin, is 
often used as a marker to prove dedifferentiation. 
 
 
Figure I-3: Schematic Diagram of Myogenic Dedifferentiation (modified from (Duckmanton et al., 2005)).  
Phenotypic dedifferentiation, cell division and cellularization all have to take place for a cell to fully 
dedifferentiate into proliferating, multipotent mononucleate cells. Two very well studied processes are the cell 
cycle re-entry, a prerequisite for organized cell division and the cellularization of multinucleated cells into 
mononucleate progeny (red circles). An upstream regulatory gene may be activated for example by local tissue 
injury and control all or some of the downstream processes. 
 
a) Fragmentation (Cellularization) 
 
The first scientist to show direct electron microscopic evidence for muscle cell fragmentation 
and population the blastema was Elizabeth Hay (Hay, 1959). The limitation of these initial 
experiments was their static nature. However, labeling and lineage tracing experiments later 
solidified Hay’s conclusions. First, explanted myotubes were used to show that muscle fibers, 
either rhodamine-dextran-labeled (Lo et al., 1993) or later retrovirus-injected (Kumar et al., 
2000) could after re-implantation contribute to the blastema and proliferate. In a very elegant 
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lineage tracing experiment in the axolotl tail Karen Echeverri was able to label single muscle 
fibers with rhodamine-dextran and followed these muscle fibers until they fragmented (Fig. I-
4) and their progeny proliferated and populated the blastema (Echeverri et al., 2001), finally 
proving that endogenous muscle fibers possess the same ability. Based on cell counting and 
Gardiner’s finding that 43 % of the blastema cell mass comes from the dermis (Gardiner et 
al., 1986), the amount of total blastema mass originating from the dedifferentiation of skeletal 
muscle fibers in the axolotl tail was estimated to be around 17% (Echeverri et al., 2001; 
Echeverri and Tanaka, 2002). 
 
Figure I-4: Tail amputation accompanied by clipping of the fiber results in dedifferentiation of a mature 
muscle fiber (Echeverri and Tanaka, 2002). 
Fluorescent images of a rhodamine-dextran-labeled muscle fiber (top panel) and overlaid with corresponding 
DIC images (bottom panel) before amputation (A, B), after amputation (C, D) and 5 days post-amputation (E, 
F). Note that the muscle fiber retracts after amputation. 5 days after amputation the labeled muscle fiber has 
fragmented into multiple mononucleated cells. 
 
b) Cell cycle re-entry 
 
It was again Elizabeth Hay who first showed that multinucleated myotubes in a regenerative 
background incorporate tritiated thymidine and thus re-enter the cell cycle (Hay, 1961). 
Later, Kumar and colleagues showed that implanted, retrovirus-labeled myotubes after 
implantation into a limb blastema gave rise to mononucleated progeny that incorporated 
 15 
BrdU, a thymidine analogue used to label proliferating cells (Kumar et al., 2000). The 
fundamental question of whether these two processes, fragmentation and cell cycle re-entry, 
are independent of each other was consequently raised in this article and answered by the 
same group within the same year (Velloso et al., 2000). Prior to transplantation, they blocked 
cell cycle progression in the cultured myotubes either by X-irradiation or by transfection of 
the CDK 4/6-inhibitor p16. This clearly showed that fragmentation of multinucleated 
myotubes into mononucleate progeny can occur independently of cell cycle progression. 
Because the goal of this thesis was to identify the molecule leading to cell cycle re-entry in 
newt myotubes, the following chapter will deal with the molecular aspects of cell cycle re-
entry. 
 
C. Molecular aspects of cell cycle re-entry and the possibility of 
dedifferentiation in mammalian cells 
 
To gain a better understanding of the molecular basis of cell cycle re-entry in 
dedifferentiation, many experiments were performed in a myogenic cell line isolated from the 
newt limb (Ferretti and Brockes, 1988). This cell line is termed A1. Upon serum reduction 
these cells can be induced to fuse and differentiate, forming a multinucleated syncytium and 
expressing typical differentiation markers such as mHC or MyoD. However, these cells lack 
some characteristics of mature myofibers, e.g. their nuclei tend to cluster together whereas 
the nuclei in mature myofibers are located more peripherally, and they also lack the typical 
striation of mature myofibers. The A1 cell line can be passaged almost indefinitely with no 
regression of cell cycle re-entry potential, making this an excellent tool to study 
dedifferentiation phenomena. Similarly, to extend these studies beyond amphibians and into 
the mammalian world, experiments are also performed in the mouse myogenic cell line 
C2C12, isolated from dystrophic mouse muscle (Yaffe and Saxel, 1977). When induced to 
differentiate by serum reduction these cells express the same set of differentiation markers as 
the A1 cells, mHC, MyoD, myogenin and Troponin T (McGann et al., 2001). In recent years, 
three different research areas proved to be especially successful and will briefly be discussed 
in this chapter. Literature in the field mainly focused on msx-1 and Bmp proteins, 
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myoseverin and small molecules or on serum and blastema extract as the main topics for the 
molecular aspects of cell cycle re-entry during dedifferentiation. Figure I-5 gives an overview 
on these different molecules and samples, and what type of dedifferentiation response they 
can induce. 
 
Figure I-5: Schematic diagram of muscle dedifferentiation in vitro (Straube and Tanaka, 2006). 
Cell cycle re-entry and fragmentation can occur independently of each other in vitro, as indicated by the curved 
arrow.  Cell cycle re-entry can be induced by blastema extract in newt A1 cells as well as in mouse C2C12 cells. 
SPRF and serum can induce cell cycle re-entry only in newt myotubes.  Fragmentation can be induced in newt 
A1 cells by blastema extract as well as by the small molecule myoseverin, whereas in mouse myotubes in 
addition to blastema extract and myoseverin Msx1 also can induce fragmentation. Interestingly, msx1 
morpholinos can inhibit fragmentation in isolated axolotl myofibers.  More details in the text. 
 
1. Msx1 and Bone morphogenetic proteins 
 
Initial evidence for the involvement of msx1, a transcription factor containing a homeobox 
domain, in newt limb regeneration was found in temporal expression studies comparing 
dedifferentiation and redifferentiation during regeneration (Simon et al., 1995). Msx1 was 
shown to be specifically expressed during the blastema stage and the early digit stage of 
regeneration but was undetectable in the adult newt forelimb and after completion of 
regeneration. Kumar and colleagues later isolated axolotl myofibers and demonstrated 
elevated levels of msx1 mRNA and protein in those cells showing morphological plasticity, 
 17 
i.e. mobilization of their nuclei accompanied by cellularization (Kumar et al., 2004). 
Moreover, fragmentation could be inhibited when msx1 morpholinos were added to the 
culture medium, leading to a reduction in msx1 protein expression. 
Msx1 seems to play a role in mouse digit tip regeneration as well. Mouse digit tip 
regeneration, which occurs in fetal and newborn mice, is limited to the area of msx1 
expression (Reginelli et al., 1995). Furthermore, Odelberg and colleagues were able to induce 
C2C12 myotubes to dedifferentiate by ectopically expressing msx1 (Odelberg et al., 2000). 
The differentiation markers MyoD, myogenin and MRF4 as well as the cell cycle inhibitor 
p21 were undetectable in 20 to 50 % of these myotubes. Clones of these myotube-derived 
mononucleated cells were shown in the same study to re-differentiate into cells expressing 
not only myogenic but also chondrogenic, adipogenic or osteogenic markers, arguing for the 
ability of mouse myotubes to even transdifferentiate into cells of other lineages given the 
correct stimuli. 
Little is known about the function of bone morphogenetic proteins (Bmp’s) during appendage 
regeneration, but they seem to be tightly linked to Msx1. Han et al. demonstrated that Bmp4 
expression coincides with msx1 expression in wild type mouse digits but is apically restricted 
in Msx1 mutants and undetectable in the digit tips of Msx1 / Msx2 double mutants (Han et al., 
2003). This effect could be rescued by endogenous Bmp4 in a dose-dependent manner. 
Furthermore, noggin, a known soluble Bmp antagonist, can be used to block cell proliferation 
in wild type digit regeneration. Thus, Msx1 and Bmp4 seem to act in a coordinated way to 
regulate mouse digit regeneration. Studies in Xenopus tadpoles show that the outgrowth of 
the regenerating tail bud is inhibited in transgenic animals containing an inducible noggin 
(Beck et al., 2006). Similar results were obtained in the limb; again, a blastema did form but 
its outgrowth was inhibited when noggin expression was induced. Interestingly, noggin also 
prevented the re-expression of Msx1 in both limb and tail blastemas and inhibited 
proliferation in spinal cord and notochord of the tail as well as in limb blastemas. Conversely, 
Han et al. place Bmp signaling downstream of Msx1 (Han et al., 2003), whereas Beck et al. 
place it upstream (Beck et al., 2006). This is likely due to differences in the animal models 
used in these studies. Recent work in planarians also confirms a role for Bmp signaling in 
planarian regeneration, being important for the formation of new tissues during regeneration 
and their dorsoventral patterning (Reddien et al., 2007). 
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2. Myoseverin and other small molecules 
 
Considerable interest in the field of regeneration was generated by the discovery of a small 
molecule that could induce fragmentation of multinucleated myotubes in vitro. Myoseverin, a 
trisubstituted purine, is a microtubule-binding small molecule depolymerizing microtubules. 
The initial morphological differentiation screen identified myoseverin as an agent that can 
induce C2C12 myotubes to reversibly fragment (Rosania et al., 2000). In this study 
myoseverin was shown to change the expression levels of many proteins involved in tissue 
regeneration pathways. Later, another small molecule with structural similarity to myoseverin 
was shown to have similar effects (Duckmanton et al., 2005). Myoseverin was also shown to 
have a similar effect on newt A1 cells (Imokawa et al., 2004a). Differentiation markers, such 
as Myf5 seem to be downregulated in mouse as well as in newt cells upon treatment with 
myoseverin. Myoseverin acts differently on myotubes than other microtubule-disrupting 
molecules like nocodazol, colchicines, taxol or vinbalstine in that its dedifferentiation effect 
is more gentle, the latter molecules often having cytotoxic effects and not being reversible in 
contrast myoseverin reverts the myotubes to a state responsive to environmental cues (Perez 
et al., 2002). These findings lead to the hypothesis that microtubule depolymerization may be 
yet another important step in muscle cell dedifferentiation and cell fragmentation in general. 
Perez et al. noted that the fragmentation occurs in the absence of cell cycle re-entry, again 
confirming that these processes are independent of each other. There is, however, some 
controversy as to the proliferative state of the mononucleated cells originating from the 
myoseverin-treated myotubes. Whereas one study observed no evidence for any proliferative 
progeny (Duckmanton et al., 2005), the other did observe DNA synthesis and cell 
proliferation after removal of the drug (Perez et al., 2002; Rosania et al., 2000). This 
dependency is likely due to differences in experimental conditions as well as a difference in 
the cell lines used (C2C12 vs. pmi28). Another small molecule, reversine, was identified in 
another screen and leads to lineage reversal of C2C12 myoblasts, enabling them to 
transdifferentiate into cells of adipogenic or osteogenic lineage (Chen et al., 2004). The 
authors argue that, as opposed to myoseverin that merely fragments multinucleated cells due 
to its microtubule-depolymerizing activity, reversine truly induces mononucleated myoblasts 
to dedifferentiate into multipotent progenitor cells that can form cells of other lineages. 
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Recently, the authors showed that reversine is active in other cell types as well and they 
suggest that it acts through inhibiting nonmuscle myosin II heavy chain and MEK1 (Chen et 
al., 2007).  
3. Serum and Blastema extract 
 
To address the question why cellular dedifferentiation normally does not occur in mammalian 
cells, McGann and colleagues purified blastema extract, a protein extract derived from 
regenerating newt limbs (McGann et al., 2001). They showed that this extract leads to 
fragmentation as well as cell cycle re-entry in both newt and mouse myotubes in vitro. The 
myotubes re-enter the cell cycle, lose differentiation markers such as MyoD, myogenin and 
troponin T and fragment into mononucleate cells, roughly 50 % of them proliferating. In 
control experiments, treatment of myotubes with mature limb extracts did not lead to any 
increase in dedifferentiation of myotubes (Odelberg, 2002). Blastema extract is a very 
complex mixture of proteins, lipids and cell debris and it is very difficult to elucidate what 
molecules in it might elicit this dedifferentiation response.  
Serum, the soluble fraction of blood after coagulation that has been used for studies on 
dedifferentiation for a long time, is somewhat less complex and also induces a 
dedifferentiation response, although it has been noted that the response induced by blastema 
extract is more complete (Odelberg, 2002). Nevertheless, serum has been an excellent source 
to study dedifferentiation in general and especially its cell cycle re-entry aspect, and this will 
be discussed more thoroughly below. The existence of a serum factor likely to be responsible 
for the re-entry into S phase has been postulated (Tanaka et al., 1999) and the factor has 
consequently been termed S phase re-entry factor (SPRF). Identification of the SPRF is the 
goal of this thesis. 
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D. A closer look at serum and cell cycle re-entry 
 
1. Newt myotubes re-enter the cell cycle upon serum 
stimulation 
 
 
 
Figure I-6: Serum stimulates newt myotubes to enter S phase (Tanaka et al., 1997).  
2 myotubes stained in green with muscle-specific myosin and Hoechst DNA stain in blue (A). The same 
myotubes stained in B for muscle-specific myosin in green and BrdU in yellow. The upper myotube has 
incorporated BrdU whereas the one on the lower left has not. Scale bar: 100 µm. 
 
A1 myotubes have been the major tool to study the effects of serum on dedifferentiation. The 
observation that A1 myotubes undergo S phase when stimulated with fetal calf serum 
(Tanaka et al., 1997) is of central importance to this thesis. In this article the authors show 
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that newt myotubes in culture transverse S phase as shown by BrdU incorporation upon 
stimulation with fetal calf serum (Fig. I-6). They also performed double labeling experiments 
with tritiated thymidine and BrdU to confirm that the DNA synthesis seen with the BrdU 
labeling is not due to DNA repair mechanisms but indeed the result of S phase re-entry and 
that the S phase in the cultured myotubes has the same length, 48-72 hours, that it has in newt 
mononucleate cells (Wallace and Maden, 1976). Another important finding of this 
experiment was that the myotubes re-enter the cell cycle without inducing apoptosis or other 
detrimental effects. 
It had been shown previously that mammalian myotubes could be induced to re-enter the cell 
cycle, for example by SV 40 large T antigen stimulation (Endo, 1989; Iujvidin et al., 1990) or 
by deletion of the retinoblastoma gene (Schneider et al., 1994). However, as opposed to 
serum stimulation this not only is a direct manipulation of the myotubes but also was 
accompanied by their degeneration. Furthermore Tanaka et al. showed that the serum-
stimulated myotubes have a DNA content of 4N, indicating a cell cycle arrest in G2. Yet 
another finding in the same study was that the serum dependent cell cycle re-entry in culture 
is also dependent on cell density. When adding mononucleate cells back to a purified 
myotube culture, as well as when the myotubes themselves are too dense, responsiveness to 
fetal bovine serum is inhibited. The serum response is not only initiated by fetal calf serum 
but also by serum of any other animal tested. 
The cell cycle re-entry activity is most likely an initial step myotubes must undergo in order 
to fully dedifferentiate and obviously is essential for proliferation. While fragmentation 
occurs independently of cell cycle re-entry, in order for regeneration to be truly epimorphic 
cells must proliferate and thus re-enter the cell cycle. The G2-M block in newt A1 culture 
seems to be a specific feature of the culture conditions, as other experiments have 
demonstrated that A1 myotubes do proliferate when implanted into animals (Lo et al., 1993). 
This might for example be due to the absence of a second factor, required to progress into M 
phase, in serum. Thus, albeit not being able to elicit the full regenerative response, the A1 
cell culture provides an excellent model system to study the initial process of cell cycle re-
entry without subsequent complications arising from mitosis, cell division and proliferation. 
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2. The role of retinoblastoma protein (pRb) 
 
As mentioned above, pRb is at the center of the differentiation pathway and is crucially 
involved in maintaining the differentiated state. Consistently, inactivation of pRb induces 
terminally differentiated mouse muscle cells in culture to re-enter the cell cycle. Similarly, 
SV40 T antigen mutants with a mutation in the pRb binding site are unable to induce the cell 
cycle (Gu et al., 1993). Moreover, although myoblasts from pRb null mice (pRb-/-) can 
differentiate into multinucleated myotubes, serum can induce dedifferentiation in those   
(pRb-/-) myotubes. Expression of p107, a retinoblastoma-like protein, is elevated during 
myogenesis, but this protein is unable to keep the myotubes in the postmitotic state upon 
serum treatment, which lowers the levels of p107 expression (Schneider et al., 1994). 
Because mouse (pRb-/-) myotubes appear to show the same characteristics as newt myotubes 
regarding serum stimulated cell cycle re-entry, the most plausible explanation for why 
urodele but not mammalian myotubes can re-enter the cell cycle upon serum stimulation is 
that pRb is either not expressed or differently regulated in urodele myotubes. Tanaka and 
colleagues addressed this question by showing that pRb is expressed in newt myotubes as 
well as in regenerating limbs and that pRb gets phosphorylated upon serum stimulation as it 
does during normal cell cycle progression (Tanaka et al., 1997). In addition, they 
demonstrated that this phosphorylation is required for the cell cycle re-entry. First, injection 
of p16INK4, a cyclin-dependent kinase inhibitor of the INK4 class, completely abolished 
serum-dependent S phase re-entry. p16INK4 inhibits the action of the cell cycle regulators 
CDK 4/6 that promote progression through the cell cycle by phosphorylation of various 
targets, one of them pRb (Lukas et al., 1995). Second, a pRb mutant with mutated 
phosphorylation sites (Hamel et al., 1992) could inhibit the serum-dependent cell cycle re-
entry by competing with endogenous (phosphorylated) pRb. Exogenous wild type pRb had a 
milder effect. 
In summary, these results demonstrate that, in contrast to mammalian myotubes, newt 
myotubes can re-enter the cell cycle in vivo. In order to do so some factor in serum must 
induce phosphorylation of pRb.  
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3. Thrombin’s proteolytic activity induces the serum response 
 
A question that immediately arises from the finding that serum can induce cell cycle re-entry 
in urodele myotubes is that of the identity of the serum factor responsible. Common growth 
factors, such as bFGF, EGF and PDGF were among the first candidates tested. However, 
none of these had any more effect on the myotubes than on their mammalian counterparts, 
although they readily acted on the mononucleated precursor cells and induced them to 
synthesize new DNA (Tanaka et al., 1999). Other substances besides single molecules tested 
in the same approach were various fractions of serum and indeed crude bovine thrombin did 
contain the activity in about 20-50 fold-purified form. Thrombin is a rather unspecific 
protease involved in the coagulation cascade, responsible for cleaving fibrinogen into fibrin 
that can then form the fibrin clot. The finding that crude bovine thrombin, a serum fraction 
that contains thrombin in an enriched yet crude form with many other proteins, can induce 
cell cycle re-entry immediately raised the question whether thrombin itself is responsible for 
the activity. Alternatively, it could exert its proteolytic activity on some other component of 
serum. To answer this question cell culture medium containing sub-threshold amounts (1.5%) 
of FBS were incubated with thrombin in the presence or absence of PPACK, an inhibitor of 
thrombin that renders the catalytic center inactive by alkylating its histidine residues (Bode et 
al., 1989). Thrombin could only generate S phase re-entry when it was not inhibited by 
PPACK, thus showing that the proteolytic activity of thrombin is essential for generating the 
cell cycle re-entry activity in serum (Tanaka et al., 1999). Interestingly, plasmin, another 
coagulation-related protease, could also generate the S phase re-entry activity while other 
proteases could not. 
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Figure I-7: Thrombin activity counteracts post-mitotic arrest in newt myotubes (Brockes and Kumar, 
2002). 
Thrombin cleaves a factor in serum or plasma (F) to generate cell cycle re-entry activity. The resulting activity 
(Fa) induces newt myotubes to re-enter the cell cycle but cannot induce cell cycle re-entry in mouse myotubes. 
As opposed to common growth factors such as PDGF, the activity does not act on mononucleate precursors, 
whereas growth factors do not act on myotubes.  
 
In addition, thrombin plays a very important role in newt lens regeneration, a process of 
regeneration in which the newly formed lens regenerates from the dorsal but not the ventral 
iris (Fig. I-8). Interestingly, this is regeneration of a distinct structure (lens) not from 
remnants of itself, but from the population of an adjacent tissue. Newt lens regeneration 
critically depends on thrombin activating pigment epithelial cells (PEC’s) from the pupillary 
margin of the dorsal iris to re-enter the cell cycle and transdifferentiate into lens (Imokawa 
and Brockes, 2003; Imokawa et al., 2004b). More than 35 years ago it was shown that five 
days after lentectomy (the surgical removal of the lens) PEC’s are the only cells at the dorsal 
papillary margin that are labeled by tritiated thymidine (Eguchi and Shingai, 1971). The label 
is then retained in the newly formed lens, proving that these labeled PEC’s populate the lens. 
In cell culture thrombin was demonstrated to activate cell cycle re-entry in PEC’s originating 
from the newt iris (Simon and Brockes, 2002). Studies of cells of the dorsal and ventral iris in 
live newts with PPACK and ATIII, another thrombin inhibitor, showed that thrombin 
inhibition reduced S phase re-entry in the dorsal cells to the background levels of the ventral 
iris (Imokawa and Brockes, 2003). However, even the newts treated with thrombin inhibitor 
progressed through some states of lens regeneration, although not until into the final stages as 
the control group did (Fig. I-8).  
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Figure I-8: Inhibition of lens regeneration after inhibition of thrombin activity on the iris post-lentectomy 
(Imokawa et al., 2004b). 
A schematic view of lens regeneration after lentectomy. PPACK (29 animals) or a control vehicle (6 animals) 
was injected into live newts and the extent of regeneration after one month is depicted in the lower part of the 
figure. PPACK significantly inhibited lens regeneration, yet did not abolish it completely. 
 
An often stated difference in regeneration in newts and axolotls, the two most commonly 
used model organisms to study urodele regeneration, is that axolotls, in contrast to newts, 
cannot regenerate their lens from the dorsal iris although they are widely known for their 
excellent regenerative capacity regarding limb or tail. Intriguingly thrombin activity is 
detectable on limb stumps of regenerating axolotls but not in the dorsal iris after lentectomy. 
This led Imokawa and Brockes to hypothesize that the axolotl’s inability to regenerate the 
lens might be due to the missing thrombin activity in the pupillary margin of the dorsal iris 
that is present in newts (Imokawa and Brockes, 2003). 
In summary, the cell cycle re-entry activity occurring in the dedifferentiation of urodele cells 
during regeneration can be initiated by high serum levels. This cell cycle re-entry is induced 
at least in newt myotubes by phosphorylation of the retinoblastoma protein pRb. 
Phosphorylation of pRb usually does not upon injury in mammalian myotubes and may be 
one of the crucial differences in the dedifferentiative capabilities between mammalian and 
urodele myotubes. The proteolytic activity of thrombin can generate the cell cycle re-entry 
activity from partially purified fractions of serum, which are a good starting point for 
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attempts to identify the soluble serum factor responsible. Moreover, thrombin can not only 
induce cultured A1 myotubes to re-enter S phase but was also shown to be necessary for newt 
lens regeneration and is active in the axolotl limb blastema. Taken together these results 
suggest a local activation of thrombin at the site of injury by activation of the coagulation 
cascade to elicit the S phase re-entry of differentiated cells. The coagulation cascade cleaves 
thrombin from its inactive into its active form, which in turn cleaves an unknown factor or an 
inhibitor of this unknown factor (Fig. I-7). 
 
E. Identification of the serum factor – Goal of and situation at 
start of thesis 
 
The goal of my thesis was to identify the thrombin-activatable factor present in serum that 
causes A1 myotubes to re-enter S phase and that likely is crucial for regeneration at least in 
urodele amphibians. 
 
1. Myotube assay – The tool for studying S phase re-entry 
 
Protocols for the myotube assay are listed in detail in Materials & Methods part A. 
A1 myoblasts were kept in culture in high serum conditions. Upon serum reduction these 
precursor cells can be induced to differentiate into myotubes.  Myotubes can then be 
separated from residual myoblasts by sieving and the larger myotubes are washed off the 
filters and plated on 96 well plates at densities between 60 and 130 myotubes per well. 
Fractions of the purification or candidate samples were then added to the myotubes, left to 
incubate for 3.5 to 4 days and then given a 12-16 hour BrdU pulse prior to fixation of the 
cells and immunostaining for myosin heavy chain (mHC) and BrdU.  Finally percentages of 
myotubes in a well that incorporated BrdU were counted. A typical well of a myotube assay 
is shown in Fig. I-9, where myotubes are stained in green (mHC) and nuclei that incorporated 
BrdU in red. 
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Figure I-9: Image of one well of a typical myotube assay. 
Differentiated myotubes expressing the differentiation marker myosin heavy chain are labeled in green; nuclei 
that incorporated BrdU are labeled in red. One red cluster of nuclei in a green myotube is counted as a positive 
myotube, a non-stained cluster of nuclei in a green myotube as negative. Red nuclei without green cytoplasmic 
staining are mononucleate precursor cells. 
 
2. Purification and characterization of SPRF 
 
As already stated above, crude bovine thrombin, the fraction of serum enriched for the S 
phase re-entry activity, provides a starting point for attempts to identify the molecular 
identity responsible for the activity. This task was started in the laboratory of Professor 
Jeremy Brockes approximately 10 years ago and it was quickly discovered that the activity is 
 28 
thrombin-inducible. Initial observations of serum showed that the S phase re-entry activity 
was not abolished by delipidation nor by dialysis with a molecular weight cutoff (MWCO) of 
6000 – 8000 Dalton, however the activity was heat labile, and boiled serum retained no SPRF 
activity. Moreover, gel filtration on Superose-12 showed that the native molecular weight of 
the activity is between 150 and 300 kDa (Tanaka et al., 1997) and this was later confirmed 
for the activity in crude bovine thrombin. These results suggested that that the activity might 
be a protein. Fractionation of crude bovine thrombin on a 1ml HiTrapQ anion exchange 
column with an increasing salt gradient resulted in two activity peaks eluting at 100 and 400 
mmol NaCl, with the 100mM fraction consisting mainly of thrombin (Tanaka and Brockes, 
1998; Tanaka et al., 1999). In addition, the activity of the 100mM fraction again co-
fractionated with thrombin on a HiTrapSP cation exchange column and eluted as one major 
sharp peak. The activity eluted from the HiTrapSP at around 500 mM NaCl and could readily 
be inhibited not only with PPACK but also with ATIII and Hirudin, all potent inhibitors of 
thrombin. The peak eluting at approximately 400 mM NaCl on the HiTrapQ anion exchange 
column however could not be inhibited by PPACK and retained approximately 40% of its S 
phase re-entry activity in serum-free conditions, as opposed to thrombin and the 100mM peak 
that is entirely dependent on serum. It is clear that the two activities separated by the anion 
exchange column are distinct from each other. The activity eluting at 100 mM NaCl contains 
most of the thrombin of the crude bovine thrombin preparation whereas the activity eluting at 
400 mM NaCl contains another activity that was generated by thrombin but is now 
independent of it. Furthermore, neither of the two peaks containing the S phase re-entry 
activity has a substantial proliferative effect on mononucleated myoblasts, as opposed to 
serum or crude bovine thrombin, which both readily induce myoblasts to proliferate (Table I-
1). Thus serum and crude bovine thrombin contain three distinct activities, the first one acting 
on myoblasts but not myotubes and likely to be associated with common growth factors such 
as bFGF, EGF or PDGF. The second activity is thrombin and the third is the activity that is 
generated by thrombin cleavage in serum, containing the S phase re-entry factor SPRF 
(Tanaka et al., 1999). All three activities can be separated from each other by simple anion 
exchange chromatography.  
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  No 
addition 
FBS Crude 
bovine 
thrombin 
Q-FT Q-100 Q-400 
A1 
mononucleates 
 - + + + - - 
A1 myotubes - PPACK / 
ATIII 
- + + - + + 
A1 myotubes + PPACK / 
ATIII 
n.a. n.a. + n.a. - + 
Table I-1: Overview of the different activities present in crude bovine thrombin and after fractionation 
on the HiTrapQ. 
All samples were added to A1 mononucleates and myotubes in the presence of 0.5% serum and S phase re-entry 
was determined in the cells. No addition as a negative control and fetal bovine serum as a positive control were 
also assayed.  Q-FT = flowthrough of the HiTrapQ column; Q-100 = 100 mM salt eluate of the HiTrapQ 
column; Q-400 = 400 mM eluate of the HiTrapQ column; n.a.: not applicable.  Whereas crude bovine thrombin 
could act on mononucleate cells and myotubes in the presence or absence of PPACK or ATIII, after 
fractionation the activities were split. Only Q-FT could act on mononucleate cells, whereas Q-100 and Q-400 
could act on myotubes exclusively. However, only Q-400 could not be inhibited by PPACK or ATIII. Table is 
based on data from (Tanaka et al., 1999). 
 
Dr. David Drechsel and Dr. Werner Straube continued the work on identifying SPRF. 
Through their experiments it became clear that SPRF is a thermolabile glycoprotein 
associating with high molecular weight complexes under native conditions and sensitive to 
proteinase K treatment (Straube et al., 2004). They showed that under denaturing conditions, 
the serum factor runs at a low molecular weight of around 30 kDa on SDS gels and possesses 
charge heterogeneity in isoelectric focusing experiments. The protein is also very robust as it 
survives denaturing conditions such as 8M urea, high pH, organic solvents and SDS. The 
purification scheme developed by Dr.’s Straube and Drechsel prior to the beginning of this 
thesis work is depicted in Table I-2. The best purification was achieved by purifying the 
crude bovine thrombin first on a weak cation exchange column (CMFF sepharose) that 
conveniently separates SPRF from thrombin and subsequent application of the flowthrough 
to a heparin affinity purification step as published (Straube et al., 2004). This led to 40-fold 
purification. Using a subsequent ultracentrifugation step with a centrifugation device 
containing a membrane with MWCO of 100 kDa  (Centricon 100) and thereafter SDS-PAGE, 
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the region between 28 and 39 kDa was estimated to be purified around 200 fold. Dr. 
Straube’s thesis work overlapped with my work, so the results achieved after the starting 
point of this thesis will be discussed at appropriate points further on. The history of the 
purification of SPRF and the work prior to the starting point of this thesis in great detail can 
be found in Dr. Straube’s thesis (Straube, 2006). 
 
 Fraction Purification (fold) 
Starting material Crude bovine thrombin 1 
Cation Exchange (CMFF) CMFF-FT 1.3 
Heparin Affinity Hep 600 mM Eluate 40 
Table I-2: The purification protocol at the start of the thesis as developed by Dr. Straube. 
40-fold purification was achieved in this 2-step protocol. Subsequent ultrafiltration with a MWCO of 100 kDa 
and analysis on SDS-PAGE led to another estimated 5-fold purification of the region of interest between 28 and 
39 kDa, thus leading to a final 200-fold purification of SPRF in-gel.  
 
Dr. Straube has done a great deal of characterization of the S phase re-entry factor in crude 
bovine thrombin or on a partially purified fraction, which was invaluable for further work on 
its purification. A short summary of these results is given in the list below: 
SPRF in crude bovine thrombin is: 
- sensitive to Proteinase K treatment 
- temperature stable up to 40°C, heat labile in between 50°C and 80°C 
- pH stable from pH 5 to pH 11 
- depleted by the lectins Concanavalin A, Jacalin, Sambucus Nigra Lectin and 
Wheat Germ Agglutinin, partially depleted by Peanut Agglutinin 
- partially inhibited by Peptide N-Glycosidase F (PNGFase) that cleaves sugars off 
the N-linked glycoproteins 
- partially inhibited in crude bovine thrombin by a 48 hour treatment with purified 
thrombin but not by treatment of 4 up to 24 hours 
- active after 24 h incubation in 1 % SDS, 8M Urea or 2 % CHAPS 
- 50 % active after precipitation in 30 – 60 % EtOH or acetone and subsequent 
reconstitution 
- precipitated by dialysis into ddH2O, but can get fully reconstituted by addition of 
1/10th volume of 10x PBS 
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- associated in a high molecular weight complex of >200 kDa under native  
- present in lower MW forms of 20 – 90 kDa at pH 11 
- present in a low MW form of around 20 kDa in the presence of SDS 
 
The first two points strongly suggest that the activity is a protein and does not stem from a 
non-proteinaceous molecule in crude bovine thrombin. The lectin experiments and the 
glycosidase experiment suggest that the activity is, or is tightly associated with, a 
glycoprotein containing glucose or mannose, N-Acetyl-Glucosamine, galactose and sialic 
acid sugars and that at least some sugar moieties are N-linked to the protein. The reduction of 
activity after prolonged incubation with thrombin is probably due to unspecific proteolytic 
activity of thrombin on SPRF, whereas the good recovery after various forms of precipitation 
or incubation in denaturing agents hints at SPRF being a very robust protein likely to survive 
a variety of chromatography techniques. 
SPRF under native conditions might loosely associate with other proteins or with itself in 
crude bovine thrombin as indicated by the concentration dependence of its apparent MW. 
However, the high molecular weight complex seems to be partially broken up by high pH, 
whereas the appearance of a sharp peak on size exclusion chromatography under denaturing 
conditions at around 20 kDa suggests that the activity stems from a single molecule. 
 
All this groundwork proved to be invaluable for this thesis and based on the above the 
thesis work was concerned with first improving the purification of SPRF, second the 
molecular testing of candidates emerging from the purification, and finally the in-depth 
analysis of a highly likely candidate in vitro and in vivo. The results obtained in these 
areas are presented below and ongoing experiments are discussed towards the end of 
the thesis. 
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II.  Results 
 
A. Purification of SPRF by chromatography 
 
All results in this section were obtained together with Dr. Werner Straube. They have also 
been described in a different way in his thesis. 
 
Fractions of the purification were assayed on myotube assays after desalting into LS-AMEM 
and all assays were performed at least in triplicates. Specific activity of fractions was 
calculated based on BrdU incorporation of A1 myotubes as explained in the introduction. 
 
The goal of this section was to develop a multistep purification protocol for SPRF from crude 
bovine thrombin to obtain relatively pure SPRF that could then be analyzed by mass 
spectrometry. Therefore, it was necessary to scale-up the first step of the initial protocol (see 
introduction) to generate sufficient material for the purification process and subsequent 
analysis, which will be discussed below. 
 
1. Scale-up of the first purification step (Cation Exchange 
CMFF)  
 
Previous work in our laboratory had established a partial purification strategy using a 5 ml 
HiTrap CMFF column to separate the thrombin away from the activity it generates. Although 
this initial step only achieved a roughly 1.3 fold purification, it was retained because it is 
necessary to remove the thrombin from the remaining preparation before proceeding with the 
purification (Straube, 2006). Residual thrombin was inactivated after this step with PPACK 
and protease inhibitors. A prerequisite for the incorporation of subsequent purification steps 
was the scale-up of the first steps of the purification scheme to obtain enough purified 
material to load on subsequent columns.  
The scale up procedure involved dissolving the crude bovine thrombin 3 times as 
concentrated as before, followed by passage of this material over a 20 ml HiPrep CMFF 
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column. For the final purification scheme, crude bovine thrombin was dissolved in cation 
buffer, pH 6.5 (see Materials & Methods), at a concentration of 24 mg/ml and loaded on a 20 
ml HiPrep CMFF column. Then, 41 ml of this crude bovine thrombin solution were loaded 
and the column was washed for 10 column volumes (CV) with cation buffer, pH 6.5.  Bound 
proteins were eluted under high salt conditions with 5 CV 1.5 M NaCl (Fig. II-1). 
Approximately 93% of the activity was recovered with a 1.4-fold purification. Importantly, 
no thrombin activity was detectable in the pooled flowthrough fractions (CMFF-FT) whereas 
approximately one third of the proteins were found in the high-salt eluate (CMFF-1.5M), 
which contained most of the thrombin. Thus, we were able to scale-up the initial purification 
step and load a 3x concentrated solution with only a minimal loss of activity while still 
removing all detectable amounts of thrombin in the flowthrough. In addition we determined 
that the CMFF-FT material can be shock frozen and stored at -80°C without any detectable 
loss of activity for at least three months. 
 
Figure II-1: Cation Exchange Chromatography – The first step of the purification. 
Chromatogram showing the fractionation of crude bovine thrombin on the HiPrep CMFF column. Crude bovine 
thrombin was dissolved in cation buffer (pH 6.5), loaded onto the column and bound proteins eluted with 1.5 M 
NaCl. FT and 1.5M NaCl eluate fractions were pooled and the FT inhibited with PPACK and PI’s. SPRF eluted 
in the FT, thrombin in the 1.5M pool. Orange bars represent the percentage of myotubes incorporating BrdU 
when treated with equal amounts of the respective fraction. 
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2. Incorporation of Butyl Hydrophobic Interaction 
Chromatography (HIC) as a second purification step, 
testing different loading conditions and scale-up 
 
As it was known that the SPRF material is relatively hydrophobic, Dr. Straube had previously 
tested various modes of hydrophobic interaction chromatography on the CMFF-FT fractions 
of previous experiments. In those tests, the butyl-sepharose resin performed better than 
valine-sepharose, phenyl-sepharose or octyl-sepharose so a butyl-sepharose column 
purification was incorporated prior to the heparin affinity chromatography step. The activity 
was known to elute in 50 mM phosphate buffer containing 20% EtOH. Since we obtained 
much more CMFF-FT material by loading higher amounts of crude bovine thrombin on the 
first cation exchange column, we also had to scale-up the second step in the final purification 
scheme. Prior to the start of this thesis the CMFF-FT pool was loaded in 1 M ammonium 
sulfate and 50 mM phosphate buffer (pH 7.0) on a 5 ml column. Because it was known from 
Dr. Straube’s previous experiments that the activity associates tightly with the butyl-
sepharose resin under these conditions, we tried to reduce the run time of this purification 
step by loading in lower salt conditions of 0.1 M ammonium sulfate, 33.3 mM phosphate. We 
also tested loading in 20 mM Tris-HCl with either 1 M or 0.1 M ammonium sulfate. Activity 
yield and purification factor were indistinguishable between high- or low-salt loading, and 
better in phosphate than in Tris buffer (data not shown), so to minimize the run time the final 
protocol uses loading at 0.1 M ammonium sulfate, 33.3 mM phosphate.  
For the final purification scheme 99 ml of the CMFF-FT pool were adjusted to 0.1 M 
ammonium sulfate, 33.3 mM phosphate buffer (pH 7.0) and loaded onto a HiPrep Butyl-FF 
column. The column was then washed for 10 CV in 0.1 M ammonium sulfate, 50 mM 
phosphate buffer before eluting in a 3-step gradient of 50 mM phosphate buffer containing 0, 
20 and 40 % EtOH. The pooled 20% EtOH fraction (Butyl-20%) contained 68% of the 
activity in 16.6-fold purified form (Fig. II-2). Thus, hydrophobic interaction chromatography 
on butyl sepharose provides a good second purification step, achieving high purification with 
little activity loss. By successfully scaling-up the first two chromatography steps, we could 
now generate sufficient partially purified material to set up a multistep purification protocol. 
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Figure II-2: Butyl Hydrophobic Interaction Chromatography – Step 2 of the purification. 
Chromatogram showing the fractionation of CMFF-FT on the HiPrep Butyl-FF column. CMFF-FT was adjusted 
to 100 mM AS, 33 mM phosphate buffer (pH 7.0), loaded onto the column and eluted with an increasing EtOH 
step gradient. As it was already known where to expect the activity only the 20% EtOH fraction was pooled. 
SPRF eluted in the 20% EtOH fraction as expected. The Orange bar indicates the Butyl-20% pool. 
 
3. Incorporation of Heparin Affinity Chromatography as the 
third purification step 
 
Once more, work in this chapter is based on previous experiments performed by Dr. Werner 
Straube.  He demonstrated that when separating the CMFF-FT fraction on a 5 ml HiTrap 
Heparin affinity column in anion buffer (pH 7.0) and a linear gradient of NaCl, the activity 
elutes between 200 and 700 mM NaCl, with good purification and yield between 430 and 590 
mM NaCl and an even higher purification but less yield between 590 and 680 mM NaCl.  
When pooling these fractions, they were designated Hep3 and Hep4, respectively. In order to 
incorporate this knowledge into the multistep purification protocol, we attempted to separate 
the Butyl-20% fraction on the 5 ml HiTrap Heparin column. 
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a) Heparin Affinity Chromatography with a step gradient elution 
 
Based on Dr. Straube’s previous results, we were confident that the heparin affinity 
chromatography step would be a good purification step. To generate a large amount of 
purified SPRF material for the testing of downstream purification steps and to account for the 
possibility that the activity would behave differently on the affinity column after being 
purified over the HIC column, we first tested the heparin column using a simplified protocol 
of a step elution gradient. Prior to the final purification run, material from a previous run was 
used for this experiment. The Butyl-20% fraction was directly loaded onto the HiTrap 
heparin column equilibrated in 20 mM anion buffer (pH 7.0) (see Materials & Methods). 
Having successfully scaled-up the first two chromatography steps, it was necessary to 
separate the Butyl-20% pool into two runs of heparin affinity chromatography, due to the 
binding capacity (~15 mg) of the HiTrap Heparin column. However, the two runs behaved 
identically and the pooled fractions could be combined afterwards.  After washing in anion 
buffer containing 200 mM NaCl, bound proteins were eluted in a 1M NaCl elution step. 
Albeit achieving only a roughly 2-fold purification, the generated material (Hep1M), was 
very useful for investigating subsequent chromatography modes (lectin affinity 
chromatography, native PAGE and gel filtration) and the recovery of around 75 % of the 
activity confirmed that SPRF still bound to the heparin affinity column after HIC and 
prompted us to investigate the linear elution step for the final purification protocol. 
 
b) Heparin Affinity Chromatography with a linear elution gradient 
 
In the final purification run, heparin affinity chromatography with a linear elution gradient 
from 0 to 1000 mM NaCl was performed. Furthermore, the Butyl-20% pool was loaded in the 
presence of 200 mM NaCl as the SPRF activity was previously shown to remain bound to the 
HiTrap Heparin column under these conditions. As for the step gradient, to prevent activity 
loss due to overloading of the column, it was necessary to split the heparin affinity step into 
two runs that were combined afterwards. These runs again behaved identically. For loading in 
200 mM NaCl, the Butyl-20% pool was adjusted to 200 mM NaCl by addition of one half of 
its volume of 20 mM anion buffer containing 600 mM NaCl. After equilibration of the 
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HiTrap Heparin column in 20 mM anion buffer (pH 7.0), 200 mM NaCl, the Butyl-20% pool 
was loaded onto the column and washed with 5 CV 20mM anion buffer (pH 7.0), 200 mM 
NaCl and 5 CV of 20 mM anion buffer (pH 7.0). Elution was performed in a 20 CV gradient 
from 0 to 1000 mM NaCl in 20 mM anion buffer (pH 7.0) and a final 5 CV step of 20 mM 
anion buffer (pH 7.0), 1500 mM NaCl (Fig. II-3).  
 
Figure II-3: Heparin Affinity Chromatography – Step 3 of the purification 
Chromatogram showing the fractionation of Butyl 20% on the HiTrap Heparin column with a linear elution 
gradient. Butyl-20% was adjusted to 200 mM NaCl with anion buffer, (pH 6.5), loaded onto the column and 
eluted with a linear gradient of increasing NaCl. As it was already known where to expect the activity, only the 
Hep3/4 fractions were pooled and the 4 fractions immediately adjacent kept as a control. SPRF eluted in the 
Hep3/4 fractions as expected. Orange bars represent the percentage of myotubes incorporating BrDU when 
treated with same amounts of the respective fraction. 
 
Based on Dr. Straube’s previous results, it was possible to pool fractions according to the 
expected elution of the activity. To obtain the best ratio of yield and activity, we pooled the 
fractions between 430 and 680 mM NaCl (Hep 3/4).  We obtained 8-fold purification in this 
step, retaining 35% of the activity. Potential residual thrombin was inhibited in the final 
purification once more at this step by addition of PPACK and protease inhibitor cocktail. In 
addition, since the protein concentration in several fractions was below 10 µg/ml, from this 
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step on, we pre-incubated all elution tubes in carrier mix prior to performing chromatography 
to prevent protein loss due to nonspecific adsorption in the tubes. In conclusion, heparin 
affinity chromatography provides a good intermediate purification step and was used as step 
3 in the final purification scheme. 
 
4. Testing of Lectin Affinity Chromatography as a possible 4th 
chromatography step 
 
Note: Incorporation of lectin affinity chromatography did not result in significant purification 
of the activity but nevertheless provided interesting results. However, it was not included into 
the final purification scheme. 
 
To test the possibility of incorporating lectin affinity chromatography into the multistep 
purification protocol, we performed test runs with the material obtained from the gradient 
elution of the heparin column. This material was purified roughly 30-fold over crude bovine 
thrombin. Based on the initial characterization experiments of the activity in a partially 
purified fraction by Dr. Straube, three different lectins were selected as possible good binding 
partners for our SPRF activity: concanavalin A (ConA), lentil lectin, and wheat germ 
agglutinin (WGA). ConA and WGA were both shown to deplete the activity and lentil lectin 
is known to bind the same sugar residues as ConA, glucose and mannose. WGA binds to N-
acetylglucosamine and N-acetylneuraminic acid. Before loading onto lectin affinity columns, 
Hep1M was diluted 1:1 in 20 mM Tris (pH 7.0) to give a final concentration of 500 mM 
NaCl. 1ml columns HiTrap lentil lectin and HiTrap WGA columns (APbiotech) and a self-
poured 1 ml ConA column were equilibrated in 10 CV binding buffer and 5ml of the diluted 
Hep1M pool were loaded onto the column. Columns were then washed in 10 CV binding 
buffer and bound proteins eluted in 10 CV elution buffer. Fractions were pooled (FT and 
eluate), and columns cleaned with 10 CV binding buffer, 10 CV regeneration buffer, 10 CV 
binding buffer and 10 CV storage buffer, in which they were finally stored. Except for elution 
buffer, lentil lectin chromatography uses the same buffers as ConA chromatography (see 
Materials & Methods). 
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Like most other proteins, SPRF did not bind to ConA and lentil lectin columns but eluted in 
the flowthrough. On the WGA column, SPRF was found in the eluate, but so were most other 
proteins. Therefore none of the lectin chromatography columns provided a good purification 
step and they were consequently not incorporated into the final purification scheme. 
Furthermore, less than 1/3rd of the activity could be recovered after lectin chromatography in 
any case. A summary of the lectin chromatography results is given in table II-1. 
Column Fraction Purification (fold) Yield (%) 
HiTrap ConA FT 0.4 12 
 Eluate 3.3 5 
 Total  17 
HiTrap lentil lectin FT 0.4 17 
 Eluate 0.8 7 
 Total  24 
HiTrap WGA FT 0.8 3 
 Eluate 0.7 31 
 Total  34 
Table II-1: Lectin Affinity Chromatography of Hep1M 
Hep1M was adjusted to 500 mM NaCl, 20mM Tris (pH 7.0) and loaded onto lectin affinity chromatography 
columns. Bound proteins were eluted with the appropriate sugar (see text). Table shows purification and yield 
for each column in FT and eluate. No good combination of purification and activity yield was achieved on any 
fraction.  
 
5. Ultrafiltration as the fourth purification step 
 
Because of the very dilute nature of the pooled fractions after heparin affinity 
chromatography as the third purification step and because the activity migrates at around 200 
kDa under native conditions, we tested the incorporation of ultrafiltration on a 100 kDa 
membrane as a fourth purification- and at the same time as a concentration step.  From 
previous experiments performed by Dr. Straube on a partially purified fraction it was known 
that most of the activity was retained by a membrane with a 100 kDa MWCO, along with 
roughly 50% of the proteins. Thus, we again expected roughly 2-fold purification with 
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minimal activity losses from performing this step on either the Hep1M or Hep3/4 pools. Prior 
to performing the ultrafiltration, the membrane (VIVASPIN membrane with MWCO 100 
kDa) was incubated in 25 ml PBS + 1.7 ml carrier mix for 2 hours.  
a) Ultrafiltration of Hep1M (after step gradient) 
 
Fourteen ml of the Hep1M pool from the heparin step gradient were first concentrated to a 
volume of 1.5 ml. The concentrated fraction was then diluted 5-fold in Tris-HCl and again 
concentrated to 1.7 ml. A fraction of this was saved and the remaining fraction again diluted 
1:1 in Tris-HCl and concentrated to 530 µl. Surprisingly, we achieved only 1.2-fold 
purification and retained only approximately 70% of the activity, but could detect a 
significant amount of activity in the first flowthrough. This was probably due to the high salt 
content (1M NaCl) of the Hep1M pool and it was thus reasoned that in the final purification 
scheme, when eluting from the heparin column in a linear gradient, this should not present a 
problem. However, even with the 30% activity loss, we obtained sufficient concentrated 
material (Hep1Mconc_200mM after the first spin and Hep1Mconc_100mM after the second 
spin) to perform initial experiments on native PAGE and gel filtration at pH 11. 
 
b) Ultrafiltration of Hep3/4 (after linear gradient) 
 
For the final purification, 48.9 ml of the Hep3/4 pool were concentrated to between 1.5 and 
1.2 ml, and then diluted with PBS to a final volume of 10 ml. This was repeated three times 
and then the pool was finally concentrated to around 750 µl (Hep 3/4). Aliquots of each FT 
were saved and assayed on myotubes and PAGE (Table II-2). No activity was found in any 
flowthrough, but surprisingly, only 61 % of the activity was retained with merely a 1.1-fold 
purification. A possible explanation for this might be that despite pre-incubating the 
Vivaspin-tube with carrier mix, a significant fraction of the proteins still bound to the 
membrane and spin-tube walls. This step was still retained for future protocols as 
concentrating the heparin pool is essential for the 5th purification step. 
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Fraction Purification (fold) Yield (%) 
Hep3/4 1 100 
Hep-FT-1 n.d. < 5 
Hep-FT-2 n.d. < 1 
Hep-FT-3 n.d. < 1 
Hep-FT-4 n.d. < 1 
Hep-FT-5 n.d. < 1 
Hep3/4-conc 1.1 61 
Table II-2: Ultrafiltration– Step 4 of the purification 
Ultrafiltration of Hep3/4. Fold purification for the concentrated material and activity yield for the concentrated 
material and flowthroughs of the Ultrafiltration step. 61% of the activity was retained in Hep3/4-conc and less 
than 10 % activity was found in all flowthroughs. 
 
6. Testing of Preparative Native PAGE as a possible fifth 
purification step. 
 
Note: Incorporation of Native PAGE did not result in significant purification of the activity. 
It was therefore not incorporated into the final purification scheme. It did, however, confirm 
the heterogeneity and the apparent high MW of the SPRF complex under native conditions 
(Straube et al., 2004). 
 
Previous experiments on a partially purified fraction after heparin affinity chromatography by 
Dr. Straube had shown that the activity could be eluted from preparative SDS-PAGE gels 
with 50 % yield in the region from 28 to 39 kDa with only 10 % of the total protein migrating 
in this region. Knowing these results and that the activity can be recovered from PAGE we 
tested whether a native PAGE step could be successfully incorporated into the purification 
scheme. If so, potential first separation based on the high MW complex (non- denaturing 
native PAGE) followed by separation based on the low MW complex (denaturing SDS-
PAGE) could have been a very powerful combination of purification steps. After the 
ultrafiltration step, we had obtained material in very concentrated form, thus enabling the 
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loading of material in small volumes. However, most proteins in our starting material for the 
native PAGE, the Hep1Mconc_100mM fraction (see above), were present in high molecular 
weight complexes not entering the stacking gel. Thus, we investigated dissociation of these 
high molecular weight aggregates by incubating the ultrafiltration material in 1% CHAPS, 
0.1% Triton-X-100 or 100 mM CAPS (pH 11) for 2 hours or by sonication for 2 hours. All of 
these treatments dissociated the complexes to various degrees with 100 mM CAPS (pH 11) 
giving the best results and consequently being chosen as the incubation step prior to native 
PAGE (Fig. II-4). Native PAGE was then carried out on 6% tris-glycine gels in non-reducing 
tris-glycine running buffer (pH 8.8) at 4°C to prevent denaturation of proteins during the run. 
Afterwards 5 lanes of the gel were cut into eight 1-cm slices and homogenized using a 
dounce homogenizer before eluting the proteins in each slice by 24 h passive diffusion at 
room temperature (RT) in PBS. Prior to desalting, remaining gel particles were removed by 
centrifugation and the supernatant was sterile-filtered.  
Unfortunately, the activity was found spread out over the top half of the gel (Fig.II-4) along 
with the majority of all proteins and thus no significant purification was achieved. Recovery 
of activity was 47 %. 
As native PAGE, which separates proteins based not only on their size but also on their net 
surface charge did not give good purification, but incubation at pH 11 clearly dissociated 
high molecular weight complexes, we next investigated size fractionation of ultrafiltration 
material at pH 11.  
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Figure II-4: Native PAGE of Hep1Mconc. 
Native PAGE of Hep1Mconc. was attempted without treatment (control), after sonication or after incubation in 
100 mM CAPS (pH 11) for 2 hours. Treatment with 100 mM CAPS facilitated entry of high molecular weight 
complexes into the gel. Thus preparative native PAGE was performed after incubation in 100 mM CAPS (pH 
11) for 2 hours. 5 lanes of the preparative gel were cut into eight regions as indicated in the rightmost lane and 
proteins eluted and tested in the myotube assay. Orange bars and numbers on the right indicate the percentage of 
myotubes re-entering S phase when assaying equivalent volumes. SPRF spreads over the top half of the gel 
along with most other proteins, thus no significant purification was achieved. Marker cocktails on the left 
demonstrate that treatments change the running behavior of some proteins but do not preclude electrophoresis.  
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7. Gel Filtration at pH 11 – purification step 5 
 
Once more, these experiments were based on previous observations by Dr. Straube. Gel 
filtration of the starting material at pH 11 shifted the activity from the high molecular weight 
complexes (>200 kDa) to below 90 kDa. We investigated gel filtration at pH 11 as a 
downstream purification step after ultrafiltration because the ultrafiltration step considerably 
cleared the region below 100 kDa into which we expected the activity to migrate. 
Furthermore, after gel filtration at pH 11 the eluate is present in a very amenable form 
because the pH can easily be changed, as opposed to, for example, gel filtration in urea or 
SDS where one would have to dialyze away the denaturing agent. Also, it was possible to 
conveniently inject the small volume in which the material was present after ultrafiltration. 
Gel filtration was carried out on a 24 ml Superdex-200 HR 10/30 column from APbiotech at 
RT in pH 11 gel filtration buffer (see Materials & Methods) after equilibrating the column in 
5 CV buffer. The pH of the starting material was adjusted to pH 11 and proteins were 
allowed to dissociate in pH 11 for at least 2 hours prior to chromatography. We first tested 
gel filtration at pH 11 on the Hep1Mconc_200mM fraction of the purification run with the 
step gradient on the heparin column (see above), before inserting it into the final purification 
scheme and applying the Hep3/4conc fraction to it. To neutralize gel filtration samples before 
desalting and assaying, one-fifth of the sample volume of 500 mM Tris (pH 7.0) was added 
to samples after the first gel filtration run.  After having found out that high molarity of Tris 
in sample fractions is detrimental to myotube assay quality, this was changed to adding 1/10th 
the volume of 1M Hepes (pH 7.4) in the final purification scheme. 
 
a) Gel filtration at pH 11 of Hep1Mconc_200mM (Table II-3, Fig. 
II-5) 
 
We obtained an excellent almost 6 fold purification and 44 % yield when pooling the 6 most 
active fractions after gel filtration at pH 11, starting from the Hep1Mconc_200mM material. 
These are unusually high numbers for gel filtration at such late purification steps and they are 
most likely due to the previous “cleaning” of the region of interest by ultrafiltration. The 
most pure fraction in this run was fraction number 32 retaining 9.4 % of the activity in 6.8-
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fold purified form. Activity eluted around a peak at 45 kDa whereas the bulk of proteins 
eluted at much higher molecular weight. Assuming a similar isoelectric point for all proteins 
in the pH 11 starting sample, native PAGE analysis across the fractions of this purification 
run shows distribution of protein complexes by size whereas non-reducing SDS PAGE shows 
that not all proteins are completely dissociated from each other at pH 11. This indicates the 
possibility of further purification by gel filtration under denaturing conditions, and it purifies 
the activity away from contaminating proteins of similar molecular weight that remain 
associated with high molecular weight complexes at pH 11, another explanation for the good 
purification in this step.  
 
GF fraction Purification (fold) Activity yield (%) 
Pool 30-35 5.8 44.3 
30 5.2 10.0 
31 5.8 9.2 
32 6.8 9.4 
33 4.6 5.5 
34 6.6 6.1 
35 5.5 4.0 
Table II-3: Gel filtration (pH 11) of Hep1Mconc_200mM: 
Purification factor and activity yield for the fractions giving best combination of purification / yield and for their 
pool are displayed. Bold letters indicate the most purified fraction. Values not adding up to 100% are due to 
rounding. 
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Figure II-5: pH 11 gel filtration of Hep1Mconc 
(previous page) 
(A) Chromatogram: Chromatogram showing the fractionation of Hep1Mconc_200mM on the SD 200 column 
on 20 mM CAPS, 200 mM NaCl (pH 11). Hep1Mconc_200mM was adjusted to 20mM CAPS, 200 mM NaCl 
(pH 11) and incubated for 2 h prior to loading to denature proteins. Orange bars represent the percentage of 
myotubes incorporating BrdU when treated with equivalent amounts of the respective fraction. (B) Non-
reducing SDS-PAGE and (C): Native PAGE, silver staining: High molecular weight complexes at pH 11 
still consist of many small molecular weight proteins (B) that co-elute at the apparent size of the complex, thus 
enabling good purification of proteins eluting in the low molecular weight region. Clear evidence of size 
fractionation is visible in (C). Equivalent sample volumes were loaded in each lane. Fractions with best 
purification / yield are shown in red (A, B and C). 
 
b) Gel filtration at pH 11 of Hep3/4conc (Table II-4, Fig.II-6) 
 
 
GF fraction Purification (fold) Activity yield (%) 
Pool 31-35 6.1 47.6 
31 3.1 6.2 
32 6.9 11.4 
33 9.3 13.7 
34 7.4 8.4 
35 5.1 4.4 
Table II-4: Gel filtration (pH 11) of Hep3/4conc – Step 5 of the purification:  
Purification factor and activity yield for the fractions giving best combination of purification / yield and for their 
pool are displayed. Bold letters indicate most purified fraction. Values not adding up to 100% are due to 
rounding.  
 
Gel filtration of Hep3/4conc. in the final purification run was marginally more successful 
than the previous experiment, the two chromatograms and the analysis of the fractions by 
SDS-PAGE looking very similar. Pooling the 6 most active fractions we obtained 6-fold 
purification with 48 % activity yield. The most active fraction 33 consisted of almost 14 % of 
the activity and was purified 9.3 fold. The activity again eluted in a peak around 45 kDa. 
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Figure II-6: pH 11 gel filtration of Hep3/4conc – Step 5 of the purification 
(A) Chromatogram: Chromatogram showing the fractionation of Hep3/4conc on the SD 200 column in 20 mM 
CAPS, 200 mM NaCl (pH 11). Hep3/4conc was adjusted to 20mM CAPS, 200 mM NaCl (pH 11) and incubated 
for 2 h prior to loading to denature proteins. Orange bars represent the percentage of myotubes incorporating 
BrdU when treated with equivalent amounts of the respective fraction. (B) Non-reducing SDS-PAGE, silver 
staining: High molecular weight complexes at pH 11 still consist of many small molecular weight proteins that 
co-elute at the apparent size of the complex, thus enabling good purification of proteins eluting in the low 
molecular weight region. Equivalent sample volumes were loaded in each lane. Fractions with best purification / 
yield are shown in red (A, B and C). 
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Summarizing, the gel filtration at pH 11 is a very good late purification step; it separates 
SPRF from its high MW interactors and retains it in an easy-to-work-with solution. This 
greatly facilitates any further chromatography step that can now be applied to separate SPRF 
based on the characteristics of its low molecular weight form, properties that have been 
neglected in the purification so far. 
 
8. Summary of the final purification scheme 
 
In summary, we established a 5-step purification protocol for SPRF from crude bovine 
thrombin achieving 1250-fold purification with 6.6 % activity yield in the final pool of six 
active fractions. The most purified single fraction contains roughly 2 % of the activity and is 
purified almost 2000-fold (Table II-5). SDS PAGE analysis across the 5-step purification 
shows clear changes in protein composition across each step (Figure II-7). However, none of 
the major bands appearing on silver-stained gels across the last purification step (Fig.II-6) 
resembles the activity profile, arguing that the activity is still only a minor fraction, even in 
the most purified sample. 
At this point it was decided to shift our focus from purification to the development of an 
assay system to test candidates emerging from mass spectrometry sequencing of partially 
purified fractions. Thus Dr. Straube focused his efforts on mass spectrometry and further 
chromatographic purification of the factor and was later joined by Ines Wagner in this effort. 
At the same time we proceeded to design the candidate testing system discussed in part B of 
the results. 
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Figure II-7: Silver staining on non-reducing SDS-PAGE across the final purification. 
0.5 µg protein from each important pool across the purification was loaded based on calculating the protein 
concentration from the absorbance at 280 nm. Red arrow points to the band representing thrombin in the crude 
bovine thrombin starting material. Red numbers mark the region where SPRF was shown to migrate in non-
reducing SDS-PAGE. Note that the total amount of protein was miscalculated in the most purified GF fraction 
33, most likely due to low levels of absorbance in gel filtration fractions. 
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Column Pool / 
Fraction 
Total 
Purification 
(fold) 
Total 
Yield 
(%) 
Step 
Purification 
(fold) 
Step 
Yield 
(%) 
Starting material Crude bovine 
thrombin 
1.0 100 1.0 100 
Cation Exchange CMFF-FT 1.4 93 1.4 93 
Hydrophobic 
Interaction 
Butyl-20% 23 63 16.6 68 
Heparin Affinity Hep3/4 183 23 7.9 36 
Ultrafiltration Hep3/4-conc 209 14 1.1 61 
Gel Filtration 
(pH 11) 
Pool (31-36) 1244 6.6 6.0 48 
 33 1937 1.9 9.3 13.8 
Table II-5: Overview of the most important fractions of the final purification 
The final purification scheme: Starting from crude bovine thrombin, SPRF is purified in a five-step purification 
protocol on cation exchange, hydrophobic interaction, heparin affinity, ultrafiltration and gel filtration at pH 11. 
The most active fraction is purified almost 2000 fold and still contains around 2 % of the activity. Shown in the 
table are purification factors and activity yields across the whole procedure as well as the individual data for 
each step. 
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B. Candidates 
 
As it became clear that the purification of SPRF to levels of homogeneity would be an 
extremely difficult and laborious task we investigated the development of different 
approaches to identify SPRF. Our approach was to identify possible SPRF candidates by 
mass spectrometry analysis of partially purified fractions of the purification. The first list of 
candidates was generated by Dr. Straube on a mass spectrometry analysis performed on a 
240-fold purified fraction of the purification. Based on this list we tested commercially 
available recombinant candidates for their ability to induce S phase re-entry in A1 myotubes, 
developed an overexpression and purification system to produce recombinant candidates, and 
finally more closely investigated a set of likely candidates. 
 
1. Candidate List – Groundwork by Dr. Straube 
 
The candidate list was generated by Dr. Straube by identifying peptides present in a sample 
generated by Dr. Straube by excising the proteins between 28 and 39 kDa of a partially 
purified (240 fold) SPRF preparation from a non-reducing SDS-PAGE experiment. The list is 
presented in Table II-6. Mass spectrometry analysis was performed by Natalie Wielsch in the 
group of Dr. Andrej Shevchenko. 
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(1) Common circulating blood proteins 
66K glycoprotein precursor - rabbit, partial 
(vitronectin) 
albumin 
apolipoprotein A1 
fibrinogen alpha chain 
fibrinogen beta chain precursor 
fibronectin 1 isoform 3 preproprotein, partial 
fibronectin precursor, partial 
thrombospondin 
 
(2) Coagulation and complement factors 
coagulation factor II [thrombin] 
coagulation factor IX (Christmas factor), partial 
coagulation factor V (proaccelerin, labile factor) 
coagulation factor X precursor (Stuart factor) 
complement component 4A preproprotein, partial 
complement component C3, partial 
complement component C4 
mannan-binding lectin serine protease 1 isoform 
 
(3) Blood transport and binding proteins 
ceruloplasmin, partial 
hemoglobin beta chain - domestic ferret 
 
(4) Protease inhibitors 
Heparin cofactor II precursor (HC-II) 
inter-alpha (globulin) inhibitor H3 
inter-alpha (globulin) inhibitor H4  
inter-alpha-trypsin inhibitor (protein HC), 
inter-alpha-trypsin inhibitor heavy chain2, 
inter-alpha-trypsin inhibitor heavy-chain H1 
(5) Proteases 
carboxypeptidase N catalytic chain precursor 
protein C prepropeptide 
 
(6) Other enzymes 
 
(7) Cytokines and hormones 
bone morphogenetic protein 4 
bone morphogenetic protein 7, partial 
 
(8) Channel and receptor-derived peptides 
 
(9) Miscellaneous (structural, nuclear, etc.) 
actin, cytoplasmic 2 (Gamma-actin) 
casein alpha-S1 
cathelicidin 1 
cytokeratin 
epithelial keratin 1, partial 
fructose-1,6-bisphosphate aldolase A, partial 
K15 intermediate filament type I keratin 
keratin 10 (epidermolytic hyperkeratosis) 
keratin 24 
keratin 25B 
keratin 4, partial 
keratin 5 (epidermolysis bullosa simplex…) 
keratin, type I cytoskeletal 14 (Cytokeratin 14) 
keratin, type II cytoskeletal 6A (Cytokeratin 6A) 
keratin, type II microfibrillar, component 5 
lumican 
myoglobin 
NEDD8 ultimate buster-1, partial 
type I keratin KA22 
Table II-6: Identified proteins after SDS-PAGE of a 240-fold purified fraction in the region between 28 
and 39 kDa (list generated by Dr. Straube).  
47 proteins were identified in a search of the LC MS/MS data against all bovine protein sequences in the NCBI 
database and classified according to (Adkins et al., 2002). Only proteins with high score are shown.  
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2. Testing commercially available recombinant candidates 
 
A commercially available subset of candidate proteins from the candidate list was tested upon 
their ability to induce S phase re-entry in A1 myotubes. We excluded keratins as they were 
probably introduced into the sample by non-sterile working conditions either during sample 
preparation or during mass spectrometry analysis. Besides keratins, we obtained all 
candidates that were commercially available and reconstituted them according to the 
manufacturer’s instructions. To confirm whether these candidate preparations could contain 
SPRF, we tested them on A1 myotubes with and without thrombin incubation. Since SPRF 
was found in serum and we cannot exclude that thrombin requires low levels of serum (or 
crude bovine thrombin) to generate SPRF from its inactive form, candidates were incubated 
with thrombin or PBS in the presence of sub-threshold levels of serum overnight at RT, 750 
rpm in a thermoshaker and then assayed on A1 myotubes. In addition, a fraction of the 
candidates was additionally spiked with a recombinant thrombin substrate and assayed by 
PAGE after incubation. Cleavage of the spike into its lower molecular weight form indicates 
thrombin activity in the spiked sample (Fig. II-8). This additional test is necessary to show 
that thrombin was active in the sample tested and not possibly inhibited by a contamination in 
the sample or by the sample itself. Serpin D1, one of the candidates and a known protease 
inhibitor, for example, could not be cleaved by thrombin and no cleavage of the spike is 
visible in this sample (lane 12 of Fig. II-8). Of all candidates tested only Bmp 4 and Bmp 7 
repeatedly showed activity in any sample and were tested in more detail. Results involving 
the Bmp proteins are shown in chapter 4, however bmp proteins did not require thrombin 
activity to induce A1 myotubes to re-enter the cell cycle.  
 55 
 
 
Figure II-8: Thrombin activation of commercially available recombinant candidates.  
Candidates were activated in sub-threshold levels of serum to facilitate thrombin dependent proteolysis. All samples were left O/N at RT to allow enough time for 
proteolysis to occur. Lane 1 shows molecular weight marker, lane 2 thrombin alone, lane 3 the recombinant thrombin substrate (“spike”) alone and lane 4 the spike 
incubated with thrombin O/N. Arrow indicates uncleaved spike, arrowheads the cleaved spike fragments. Note the cleavage of the 40 kDa spike (lane 3) into two 30 
kDa and 10 kDa fragments (lane 4). In each sample, if thrombin was active, cleavage of the spike is seen. Note that Serpin D1, a known protease inhibitor, inhibits 
thrombin activity and no cleavage of the spike occurs (lanes 11 and 12). None of the candidates shown here repeatedly displayed activity in the myotube assay, in
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neither thrombin-treated nor untreated form. Carboxypeptidase N has not been assayed on gel in mock-treated 
form because of sample shortage, but has been tested in the myotube assay in both ways. 
 
3. Developing an overexpression and purification system to 
produce recombinant candidates 
 
To obtain promising candidates in larger quantities and to be able to cost-effectively screen 
through a high number of other potential candidates that might arise from future mass 
spectrometry analyses, we developed an overexpression and purification system to produce 
recombinant candidates. Since our activity originates from a mammalian system, we chose 
the Freestyle 293 expression system (Invitrogen) to overexpress our candidate genes. This 
system is very well suited for the overexpression of secreted and glycosylated proteins in 
serum-free conditions, all three features being important for these experiments. First, 
secretion into the culture medium omits the need for lysing cells in the process of 
purification. Second, a correct mammalian glycosylation pattern might be important for the 
activity, and third, since serum contains our activity, serum-free overexpression conditions 
are essential. The overexpression and purification system was set up with vitronectin as a first 
candidate (Fig. II-9). First, vitronectin was cloned into an overexpression vector generated by 
Mike Tipsword and overexpressed in the Freestyle 293 expression system. The vector was 
designed so that the candidate was fused to a cleavable Fc-tag and secreted into the medium. 
Supernatant was then concentrated and loaded onto a Protein A column to bind the fusion 
protein. The candidate was subsequently eluted from the column by cleavage with 3C 
protease at the introduced cleavage site between the candidate and the Fc-tag. Purified 
vitronectin was then tested for functionality by coating cell culture dishes. A1 myotubes 
adhered better on vitronectin-coated cell culture dishes than on mock-coated dishes (Figure 
II-9). 
In summary, we were able to establish a purification and overexpression system to 
recombinantly overexpress biologically active candidates fused to a cleavable Fc-tag and 
secreted into the culture medium. After obtaining candidates with this system they can then 
easily be tested on A1 myotubes as described in the previous chapter. As in all 
overexpression systems, efficiency of overexpression depends on the candidate gene and 
 57 
must be tested for each candidate individually. In a later experiment, we were able to 
overexpress Bmp 4 and Bmp 7, alone and in combination with each other, in this system, but 
yields were very low.  
 
 
Figure II-9: The overexpression- and purification system for candidates.  
(A) Fusion protein generated from the overexpression vector: Candidates are expressed as fusion proteins 
containing an N-terminal signal sequence and a C-terminal Fc-tag behind a 3C protease site. (B) Cartoon of the 
candidate purification: After overexpression in the Freestyle 293 system supernatant from the cells is loaded 
on a protein A affinity column to which fusion proteins bind via the Fc-tag. 3C protease is then added to the 
column and after 90 minutes incubation at 4°C, cleaved candidate protein is eluted from the column. (C) 
Overexpression of vitronectin-Fc: Western Blot against the Fc-tag. As expected, overexpression of 
Vitronectin-Fc results in a fusion protein of about 100 kDa. (D): Purification of vitronectin on a protein A 
column: Reducing SDS-PAGE, equal volumes loaded: 500 ml sterile-filtered conditioned supernatant was 
loaded on a protein A column, washed, incubated with 3C protease and concentrated vitronectin eluted. Lane 1: 
MW marker; lanes 2 - 7: loading controls (FT 1 = 1st 10th of loading; FT 2 = 1st half of loading; FT 3 = 2nd half 
of loading); lanes 8 – 10: Eluates after 3C protease cleavage. Note that cleaved fusion protein elutes at 
approximately 75 kDa, the expected size of vitronectin. (E): Eluted vitronectin promotes cell adhesion on cell 
culture plastic. Green fluorescent channel image of one well of A1 myotubes in a 96-well plate, stained with 
fluorescein-coupled mHC antibody. A1 myotubes adhere better in wells coated with eluted vitronectin than in 
mock-coated wells, suggesting functional protein was eluted.  
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4. Bmp proteins specifically induce S phase re-entry in A1 
myotubes 
 
As mentioned previously, Bmp 4 as well as Bmp 7 showed activity in the myotube assay. As 
Bmp proteins exist in dimers, we further investigated which form of dimer could generate 
activity in our assay, and whether there is a difference between homo- and heterodimers 
regarding activity. We therefore performed dose response experiments with the Bmp 4 
homodimer, the Bmp 7 homodimer, a combination of the two homodimers and also with the 
Bmp 4/7 heterodimer (Fig. II-10a). Interestingly, all combinations tested could generate a 
response, but the Bmp 4/7 heterodimer was two orders of magnitude more potent than either 
homodimer or the combination of the two homodimers. To eliminate the possibility that the 
Bmp-induced activity was generated by a contamination in the Bmp preparation we 
performed another dose response experiment on A1 myotubes: An amount of Bmp 4/7 
heterodimer that was known to generate a response of about 15 % was mixed with various 
amounts of noggin, a known inhibitor of Bmp proteins and this mixture was added to the 
wells. Noggin acts by binding to the Bmp dimer, thereby preventing the binding of the Bmp 
dimers to their cellular receptors by physically blocking the binding site. Indeed Bmp 4/7–
induced activity could be inhibited by noggin-Fc in a dose dependent manner (Fig. II-10b), 
strongly suggesting that the Bmp-induced activity in the myotube assay is not due to 
contamination of the candidate (e.g. residual proteases from its generation), but is specifically 
induced by the Bmp protein. In addition, Noggin could also inhibit Bmp 4-induced activity 
(data not shown) as well as the Butyl-20% fraction of the SPRF purification (Ines Wagner, 
unpublished data).  
 
Since the discovery of SPRF activity more than 10 years ago, Bmp proteins are the first 
candidate molecules obtained from the purification of SPRF that could specifically and 
reproducibly induce A1 myotubes to re-enter S phase. 
 
We therefore decided at this point to abandon further purification efforts and focus on 
investigating Bmp proteins in vivo during urodele regeneration. Furthermore, Ines Wagner, 
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who joined the project in the meantime, shifted her work from purification to biochemical 
characterization of Bmp proteins in crude bovine thrombin. Part C of the results shows data 
obtained from in vivo studies of Bmp proteins in regeneration. Some of Ines Wagner’s results 
will be mentioned in the discussion, where appropriate.    
 
Figure II-10: Bmp’s specifically induce S phase re-entry in A1 myotubes.  
(A): Bmp dimers generate S phase re-entry in A1 myotubes. Dose response experiments with different Bmp 
dimers on A1 myotubes. Note that Bmp 4/7 heterodimer is approximately 100 times as potent as 4/4 
homodimer, 7/7 homodimer or 4/4 plus 7/7 homodimer, however all of the Bmp dimers can generate S phase re-
entry activity. (B): Noggin-Fc inhibits Bmp-induced S phase re-entry. When Bmp 4/7 heterodimers were 
incubated with noggin-Fc for 1 hour prior to addition to A1 myotubes, noggin-Fc could block Bmp-induced S 
phase re-entry in a dose dependent manner, showing a specific correlation between Bmp activity and S phase re-
entry. Graphs were created with the Graphpad Prism software, constraints for the non-linear fit in (A) were: 
minimum > -5; max < 50; slope =1 and for all but the heterodimer: max = max (heterodimer), in (B): max < 30; 
min > -5. Error bars in (A) are omitted for clarity. 
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C. Inhibiting tail regeneration in vivo by blocking Bmp signaling 
 
As the results obtained with the Bmp’s and noggin were very promising, we investigated the 
role of Bmp signaling during regeneration in live urodeles. The results obtained to date are 
displayed in this chapter. 
 
1. Noggin inhibits regeneration when injected into regenerating 
axolotl spinal cord 
 
 
Figure II-11: Overexpression of Noggin-Fc causes severe regeneration defects in axolotl tails. 
Control plasmid (left side) or plasmid containing Noggin-Fc DNA (right side) was injected into the spinal cord 
of 1.5 - 2.5 cm axolotl larvae together with a reporter plasmid and electroporated. Tails were re-cut after 3 days 
through the area of enhanced expression of the transgene. Regeneration was followed for 14 days. Noggin-Fc 
treated animals showed several defects in regeneration: shorter overall regenerate, less muscle formation, 
“folded” tails and “tissue blebs” and sometimes a “bent” spinal cord. Green and red fluorescence show 
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expression of co-injected reporter plasmid in cytoplasm (green) and nuclei (red). Scale bar on the lower right 
represents 1 mm. a = anterior; p = posterior. 
 
Initially we investigated the role of Bmp signaling in urodele regeneration in axolotl tails by 
inhibiting Bmp signaling in the axolotl spinal cord. We thus injected Noggin-Fc together with 
one of two reporter plasmids coding for either green or red and green fluorescence into the 
regenerating axolotl spinal cord of 1.5 – 2.5 cm axolotl larvae. After re-amputating the 
injected tails through the region of strong transgene expression, regeneration was followed 
for 14 days (Fig. II-11). We observed a pronounced defect in regeneration in noggin-Fc 
treated animals as opposed to empty vector injected control cases. Overall fin morphology 
was grossly disturbed, the fin seemed to be inhibited in overall growth and aberrant folding 
of the fin occurred with some of the folds growing into each other. Secondly, we observed a 
strong defect in cartilage outgrowth. In comparison to control animals, where the formation 
of cartilage ventral to the regenerating spinal cord begins around 7 days post amputation 
(dpa) and a long rod of cartilage is visible 10 dpa, no cartilage was detectable in noggin-Fc 
injected cases at 7 dpa (Fig. II-12) and cartilage first appeared 10 dpa (Fig. II-13). In 
addition, the appearance of organized myotomes posterior to the amputation plane could not 
be detected in noggin-Fc injected animals up to 10 dpa, whereas myotome formation was 
clearly visible in control animals between 7 (Fig. II-12) and 10 dpa (Fig. II-13). Although 
some muscle fibers are visible posterior to the amputation plane in noggin-Fc-injected 
animals, they are not organized as neatly in myotomes as in control cases. Even 19 dpa no 
myotomes could be detected in noggin-Fc injected animals posterior to the amputation plane 
based on tail morphology, however, no immunostainings were performed at this late time 
point. Interestingly, outgrowth of the spinal cord itself appears to be overall normal, the 
spinal cord appears to grow too quickly for the rest of the fin and was observed to bend in 
some cases, presumably because the fin cannot grow at the same rate as the spinal cord. 
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Figure II-12: After 7 days of regeneration, Noggin-Fc-injected animals show a defect in cartilage 
outgrowth and muscle formation posterior to the amputation plane.  
Images of 4 different animals for each condition. Tails were stained with Alcian Blue and anti-MHC antibody 
(red). Green: co-injected GFP. In 3/4 control cases 7 dpa the cartilage rod has started to grow from the 
amputation plane. At this timepoint, myotomes begin forming posterior to the amputation plane (left panel). In 
Noggin-Fc-injected animals, no regular myotomes have formed posterior to the amputation plane and no 
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cartilage rod can be seen after 7 dpa (right panel). Also note the irregular overall fin structure in Noggin-Fc- 
injected animals, e.g. the “split fin phenotype” (arrows). a = anterior; p = posterior. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-13: After 10 days of regeneration Noggin-Fc-injected animals show no formation of regular 
myotomes posterior to the amputation plane, the cartilage rod is only beginning to form and overall fin 
structure is disturbed.  
(next page) 
Images of 4 different animals for each condition. Tails were stained with Alcian Blue and anti-MHC antibody 
(red). Green: co-injected GFP. In 4/4 control cases 10 dpa the cartilage rod has grown substantially and 
myotomes have formed posterior to the amputation plane (left panel). In Noggin-Fc-injected animals no regular 
myotomes have formed posterior to the amputation plane and the cartilage rod is just beginning to form in 2/4 
cases (right panel). If muscle fibers formed at all, they were disorganized. Also, overall fin structure is disturbed 
and the overall regenerate size is smaller in Noggin-Fc-treated animals. a = anterior; p = posterior 
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2. Dorsomorphin blocks regeneration of axolotl tails.   
 
In a second set of experiments we investigated whether Dorsomorphin, a small molecule, 
caused similar effects to those observed after noggin treatment. The advantages of a small 
molecule are easy administration to the animal and a very reproducible dosage adjustment as 
it can be transmitted very easily through the water. Dorsomorphin was initially identified as a 
AMPK inhibitor, however, recent work has shown that it also inhibits Bmp signaling in 
developing zebrafish embryos and that this effect was independent of AMPK signaling 
(Anderson and Darshan, 2008; Yu et al., 2008). As opposed to noggin, Dorsomorphin acts 
intracellularly, inhibiting the BMP type I receptors ALK2, ALK3 and ALK6, thereby 
preventing phosphorylation of SMAD 1/5/8 by the downstream Bmp signaling. 
Overall, the effects of Dorsomorphin treatment were similar to those observed after noggin 
treatment. Again, regeneration of axolotl tails was inhibited, and fin morphology and 
cartilage formation in the regenerate were affected (Fig. II-14). Muscle formation has not yet 
been assayed, as both control and Dorsomorphin-treated animals appear to grow slower and 
no convincing phenotype was observed 7 or 10 dpa. Most likely, this slower growth is linked 
to the experimental conditions as, due to the light-sensitivity of the drug, animals in this 
experiment were kept in confined spaces in the dark. The observation of the reduced growth 
is also based on the total length of the regenerating spinal cord and the cartilage rod; both 
seem to be shorter in the dorsomorphin experiments compared to the injections. Further 
experiments are currently underway. 
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Figure II-14: Dorsomorphin causes regeneration defects in axolotl tails.  
Alcian Blue staining for cartilage. In 2/2 control cases (left panel) cartilage rod formation begins at 7 dpa and 
outgrowth is visible at 10 dpa (2/2) whereas in Dorsomorphin-treated animals (right panel) no cartilage rod is 
visible at 7 dpa (2/2) or 10 dpa (2/2). Fin growth is impaired in Dorsomorphin-treated animals as well. Note that 
almost no regeneration occurred in one Dorsomorphin-treated animal 10 dpa (arrow). a= anterior; p = posterior. 
Scale bars: 1 mm 
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III.  Discussion 
 
The ability of urodele amphibians to regenerate lost body parts or organs is truly a wonder of 
nature. Dedifferentiation of differentiated cells might be one way to achieve the proliferative 
capacity needed to supply the regenerating structure with new cells. The other one might be 
the activation of resident stem- or progenitor cells. While activation of resident stem- or 
progenitor cells seems to be relatively widespread amongst various species, the ability to 
dedifferentiate cells as a response to injury is more restricted. This ability does not correlate 
exclusively with the occurrence of regeneration as for example xenopus tadpoles can 
regenerate without dedifferentiation. However, it might be possible that species that cannot 
regenerate could be induced to regenerate when enabling dedifferentiation of cells close to 
their site of injury. But even if this goal is far away, the deciphering of the molecular 
pathways leading to regeneration can substantially enhance our understanding of the process 
of regeneration. As one of the processes involved in regeneration is cell cycle re-entry, 
identifying the factor that initiates cell cycle re-entry of differentiated cells might greatly 
enhance our knowledge about regeneration. 
The existence of the factor was postulated in 1997 when Tanaka et al. found out that serum 
from various animals could initiate S phase re-entry in A1 myotubes (Tanaka et al., 1997). 
Very quickly it was discovered that the factor is activatable by thrombin and plasmin and 
prior to this thesis work the molecular characteristics of this S phase re-entry factor were 
investigated and a multistep purification protocol to identify it was started to set up.  
We provide strong evidence that SPRF is a Bmp family member and are very close to 
showing whether it is the Bmp 4/7 heterodimer or another Bmp family member. The 
evidence includes that Bmp family members were identified in mass spectrometry in late 
fractions of our purification, the bmp 4 abundance correlated with the activity profile across 
the final purification step and increased during the purification (Ines Wagner, unpublished 
data). Moreover Bmp family members were the only pure proteins reproducibly inducing A1 
myotubes so re-enter S phase and they did so in a dose-responsive fashion. Furthermore, 
noggin-Fc, a known extracellular inhibitor of bmp signaling could block this response in a 
dose-dependent manner and as well as Dorsomorphin, an intracellular inhibitor of bmp 
signaling, it could also block tail regeneration in axolotl larvae.  Thus, in vivo as well as in 
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vitro evidence for bmp family members as important molecules in regeneration could be 
gathered and SPRF could be identified as a bmp family member. 
We will here discuss the results obtained in this thesis’s work in some more detail and 
mention some ongoing experiments to definitely prove the identity of SPRF and strengthen 
the link between in vitro and in vivo data obtained. 
 
A. Purification of SPRF 
 
We managed to set up a 5-step purification protocol, purifying the activity almost 2000-fold. 
As crude bovine thrombin is already 20 fold purified above serum for the activity (Tanaka et 
al., 1999), we obtained a roughly 40 000-fold purification above serum. However, as can 
clearly be seen from the gels across the whole purification (Fig. II-7) as well as across the 
final purification run (Fig. II-6B), this is still far from homogeneity. Furthermore, none of the 
major bands visible on the gel across the final purification step matches the activity profile 
across this step, arguing that the activity is not one of the ten major components of the 
fraction. This implicates that achieving homogeneity in a purification starting from a sample 
as complex as serum (or crude bovine thrombin) can be extremely difficult. Furthermore, the 
absence of any major band matching the activity profile illustrates that our activity must be 
very potent, again making it rather difficult to purify to homogeneity. 
However, we are confident that we could identify the SPRF from our partially purified 
fractions based on the following calculations: 
Assuming that the activity is present at growth factor levels (0.1 – 10 nM) and is a 30 kDa 
protein, it would be present at 3 – 300 ng/ml in serum. Assuming further that proteins are 
present in serum at around 60 - 80 mg/ml and from the fact that 10 % FBS generate full 
activity on A1 cells, SPRF would make about 4 to 500 ppm in serum. Thus, to obtain pure 
protein, we would have to obtain a 2 000 to 250 000-fold purification above serum. As 
mentioned before, we are well within this scale. By cutting out a faint candidate band slightly 
below the major 30 kDa band, matching the activity profile across the gel filtration run of 
Hep3/4 (Figure II-6), we could obtain another 25-fold purification, raising the total 
purification factor to 1 000 000 above serum, which would then be above this scale. 
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Moreover, recent advances in the mass spectrometry field have made protein sequencing by 
mass spectrometry an excellent tool to identify proteins, even in only partially purified 
samples. Mass spectrometers nowadays can detect less than 100 fmol of a protein, enabling it 
to detect 3 ng of a 30 kDa protein. Given that SPRF would be the candidate band, we know 
from quantification of the gel in figure II-7 that it consists of around 4 % of the total protein 
in the most purified gel filtration fraction. Starting the purification from 1 g of crude bovine 
thrombin (= 777 mg protein), we could recover about 4 µg of total protein in the most 
purified fraction. 4 % of these 4 µg would make roughly 160 ng, more than 5000 fmol of a 30 
kDa protein, in other words:  more than 50-fold of what the mass spectrometer would need. 
Even if the candidate band would partially consist of contaminating proteins or if post-
translational modifications, such as glycosylation, would preclude the identification of some 
tryptic peptides in the mass spectrometry analysis, this should still be sufficient for confident 
identification of SPRF. Indeed, mass spectrometry attempts on more purified samples than 
the initial attempt displayed in the results section, and even on the candidate band correlating 
with the activity profile in the gel filtration run, did not modify the candidate list in any major 
way (i.e. did not generate many new high confidence hits), with the exception that Bmp 5 
could also be detected. 
All this makes us confident that a candidate protein identified by mass spectrometry from our 
purification could be present in serum in a biological meaningful concentration and that it is 
unlikely that we missed many proteins still present in the most purified sample at growth 
factor levels. 
 
After Bmp proteins were found to specifically induce A1 myotubes to re-enter S-phase, and 
the Bmp 4/7 heterodimer did so at concentrations between 1 and 10 ng/ml, all efforts to 
advance the purification were terminated.  
 
B. Overexpression system 
 
In order to test the candidates obtained from mass spectrometry analysis, we managed to set 
up an overexpression and purification “assembly line” to generate candidates recombinantly 
in serum-free culture conditions.  
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The advantages of the system include the overexpression in serum-free medium, especially 
important for this project as serum contains the S phase re-entry activity. Next, candidates 
produced in the mammalian 293 cell line are produced with a mammalian glycosylation 
pattern, another important aspect of this cell line, because a wrong glycosylation pattern on a 
candidate protein might diminish the activity. A third advantage is the secretion of the 
produced candidates into the culture medium, facilitating the harvest of the overexpressed 
protein and making the system suitable for medium throughput analysis of candidates. 
A disadvantage is that proteins were overexpressed with varying efficiency. Vitronectin, for 
example could be expressed and purified on the system with comparatively high yield of up 
to 8 µg/ml, resulting in the production and collection of functional protein. Bmp 4 
homodimer on the other hand was also tested but could not be overexpressed in high amounts 
and yielded only about 5 µg / l of culture medium. This might be because the Bmp proteins 
might get bound to the surface of the cells after secretion into the medium or due to problems 
in the secretory pathway as some of the Bmp 4 could be found in the cell pellet after the 
harvest. Mysteriously, after 3C protease-induced elution from the protein A column, we 
noted a roughly 50 kDa band in the eluate from the Bmp 4-induced culture supernatant that 
was not recognized by the Bmp 4 antibody used to detect the much smaller amounts of Bmp 
in the medium. 
Irrespective of the advantages and disadvantages of the system, with the finding that Bmp 
proteins specifically induce A1 myotubes to re-enter S phase and the abandoning of the 
purification project there was no further need to use the overexpression system to produce a 
large diversity of recombinant candidates. Still, the 293 system proved to be worth setting up. 
While we moved on to test the commercially available Bmp proteins in the myotube assay 
and started the initial in vivo experiments on axolotl larvae, Ines Wagner utilized and further 
developed the 293 cell overexpression system to recombinantly produce Bmp proteins and 
noggin for biochemical studies.  
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C. Is Bmp 4/7 the SPRF?  
 
The most obvious question arising from the data presented in this thesis of course is whether 
Bmp 4/7 indeed is SPRF. We do not have a final answer yet, but the collected evidence 
strongly suggests this conclusion. 
Bmp 4 as well as Bmp 7 was found in the mass spectrometry analyses of purified fractions 
and Ines Wagner could later show that Bmp 4 amounts in western blots across the fractions 
of the gel filtration at pH 11 and across the late steps of the purification correlate with the 
activity data. We are currently investigating whether the same is true for Bmp 7.  The Bmp 
4/7 heterodimer as well as both homodimers could specifically induce A1 myotubes to re-
enter S phase in a dose-dependent manner, whereas no other protein identified by mass 
spectrometry could elicit a response. In doing so, the heterodimer is about 100 fold as potent 
as either homodimer or a 1:1 combination of the two homodimers. Moreover Bmp 4/7 in the 
myotube assay acts at similar concentrations as growth factors do in other tissues. Also, no 
other protein identified by mass spectrometry could induce A1 myotubes to re-enter S phase 
and we are confident that we identified most, if not all other proteins still present in the most 
purified fraction of the purification at similar levels. 
We excluded the possibility that the activity might be a contamination in the Bmp 
preparation, for example a residual protease from its generation. Noggin-Fc, a known 
inhibitor of Bmp signaling was shown to completely block this response, again in a dose- 
dependent manner. The ED50 for the inhibition of Bmp 4-induced alkaline phosphatase 
production in ATDC5 cells, the standard measure for noggin inhibition, is between 0.06 and 
0.3 µg/ml in the presence of 75 ng/ml Bmp 4 (R+D systems). Clearly within the same order 
of magnitude, the ED50 for the inhibition of Bmp 4/7-induced S phase re-entry of A1 
myotubes is between 0.01 and 0.1 µg/ml in the presence of 5 ng/ml Bmp 4/7 (Fig. II-10). 
Importantly, noggin-Fc could also completely inhibit Bmp 4 homodimer and the partially 
purified Butyl-20% fraction from inducing A1 myotubes to re-enter S phase. Not only did 
noggin-Fc inhibit the Bmp-induced activity but also was the activity present in three different 
preparations (Bmp 4; Bmp 7; Bmp 4/7) at various amounts and Ines Wagner in the meantime 
managed to generate Bmp proteins in the 293 expression system and could also see activity 
induced by those. In addition, she managed to deplete the activity along with Bmp proteins 
from a partially purified fraction of crude bovine thrombin with recombinant noggin-Fc. 
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Finally, inhibition of Bmp signaling in vivo by either noggin-Fc or by Dorsomorphin could 
block axolotl tail regeneration. 
All this evidence strongly suggests Bmp 4/7, or at least Bmp family members as SPRF. The 
fact that the heterodimer is two orders of magnitudes as potent as the homodimers suggests 
that either the heterodimer is the true activity whereas the activity in the homodimers might 
be a heterodimer contamination, or that the heterodimer is simply more efficient at clustering 
different receptors on the cell surface. But the question is still open whether SPRF is truly 
Bmp 4/7 or another Bmp family member. For example, Bmp 5 was also identified in later 
mass spectrometry analyses. The activity could thus also be a Bmp x/5 heterodimer, where x 
stands for any other Bmp protein. Furthermore, no evidence for Bmp 4 in urodele amphibians 
was found so far and extensive EST sequencing in our laboratory failed to identify a Bmp 4 
sequence. It is thus feasible that urodele amphibians could use a different subset of Bmp 
proteins for the same purposes and thus more than one combination of Bmp family members 
could account for the activity.  
We are currently investigating the depletion of Bmp 4/7 from partially purified fractions of 
crude bovine thrombin with molecules more specific for Bmp 4/7, e.g. monoclonal antibodies 
recognizing only one Bmp family member, as well as add-back experiments into depleted 
fractions. This should very soon enable us to definitely conclude whether SPRF in crude 
bovine thrombin is indeed Bmp 4/7 or might still be some other Bmp family member. 
 
D. Relationship of Bmp proteins to other molecules in 
regeneration 
 
1. Serum, crude bovine thrombin and thrombin-activation 
 
Our experiments suggest that Bmp proteins are the sole molecules in serum responsible for 
the S phase re-entry response as noggin-Fc inhibition can completely block the response 
generated by the partially purified Butyl-20% fraction of crude bovine thrombin. An 
important aspect of this response was whether this Bmp-induced response is serum-
dependent or not. Ines Wagner succeeded in answering this question by showing that Bmp 
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proteins can also induce S phase re-entry activity in A1 myotubes under serum-free 
conditions. 
The high molecular weight of the activity in crude bovine thrombin and serum suggests that 
the Bmp proteins are associated in some multiprotein-complex in serum. Interestingly, 
recombinant Bmp proteins exhibit the activity without the need for thrombin-activation. 
Together, these data suggest that Bmp proteins are either complexed in an inactive pro-form 
with other molecules, or they are complexed with some inhibitory molecule in serum (and 
crude bovine thrombin) and that thrombin activates the Bmp proteins in serum by cleaving 
the inhibitory molecule. This might also provide an interesting link towards injury in in vivo 
systems. Thrombin-dependent proteolysis, locally activated at the site of injury to produce 
the fibrin clot, in addition might cleave the Bmp-inhibitory molecule or the inactive pro-form 
and thus promote regeneration. This might provide a mechanism to conveniently restrict 
activation of Bmp signaling and thereby dedifferentiation to the vicinity of wounds and 
prevent aberrant dedifferentiation in the rest of the body. However, this local restriction of 
the activity would not be dependent on fibrin, as in newt lens regeneration, which is critically 
dependent on thrombin (Imokawa and Brockes, 2003; Imokawa et al., 2004b), there is no 
fibrin clot involved in the regenerative response and the activity is restricted to the dorsal iris. 
Another possibility would be that the Bmp proteins in serum, but not the recombinant ones, 
are present in some precursor-form and need thrombin-dependent proteolysis to get cleaved 
into their active form. Unfortunately, we could not detect any Bmp family members by 
western blot on crude bovine thrombin, as it probably is present below detection levels, even 
when concentrating 10-fold.  Thus, we cannot conclude whether the Bmp family member is 
present in its mature form or in a pro-form that still has to be cleaved. 
 
2. Blastema extract 
 
Having found that Bmp proteins are responsible for the activity in serum, another interesting 
set of experiments would be to determine whether they could also be detected in blastema 
extract obtained from axolotl or newt. It would be very interesting to see if noggin-treatment 
of blastema extract would lead to an inhibition of the dedifferentiation response induced by 
blastema extract and to what extent this would occur. For example, noggin-treatment of 
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blastema extract might inhibit only the cell cycle re-entry activity but not the fragmentation 
of multinucleated myotubes. On the other hand it might also inhibit both. Or maybe it would 
affect neither, as another molecule present in the blastema extract might take over and push 
the myotubes through the cell cycle. Having identified Bmp proteins as the mediators of 
activity in serum, experiments with Bmp proteins, noggin and blastema extract could greatly 
enhance our knowledge on regeneration. 
 
3. Msx1 
 
Bmp proteins and Msx1 have been implicated to act together in regeneration in different 
model organisms (Beck et al., 2006; Han et al., 2003), but as mentioned in the introduction, 
there is dispute about which molecule signals to the other one. Experiments in urodele 
amphibians might provide another indication of the relationship between Bmp proteins and 
Msx1 and might help to clarify the situation. It would for example be interesting to determine 
if the inhibition of Bmp signaling would affect the msx1 levels in regenerating amphibian 
limbs or whether inhibiting msx1 induced transcription would affect Bmp levels. Both are 
presumably not easy experiments to do as both molecules might be present in very low 
amounts in the regenerating tissue but this could again serve to better understand the 
molecular processes of regeneration 
 
E. Cell cycle re-entry in urodele limbs and tails 
 
The A1 cell line originates from newt limbs but so far all in vivo experiments were performed 
in axolotl tails. To generate a stronger link between the in vitro data from the A1 myotube 
assays and the in vivo data, we are currently performing experiments in axolotl as well as 
newt limbs. We are planning to inject BrdU or another thymidine analogue into regenerating 
animals and assay their incorporation into differentiated limb muscle cells at various points 
through regeneration. We plan to do this in animals treated with a Bmp inhibitor as well as in 
a control population. If Bmp proteins truly are SPRF, one would expect overall reduced limb 
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regeneration in the treated animals as well as a decrease in BrdU incorporation in 
dedifferentiating muscle. 
This phenotype would tightly link regeneration in vivo to the A1 cell culture data, proving 
that the activity seen in cell culture can also act very similarly in live animals, Furthermore, 
together with the in vivo tail data this would also argue that the activity might not merely act 
on muscle cells. It is very unlikely that inhibiting only muscle cell dedifferentiation would 
cause such an extensive tail regeneration defect as muscle cell dedifferentiation accounts for 
roughly 17 % of the blastema tissue (Echeverri et al., 2001; Echeverri and Tanaka, 2002). In 
addition, our in vivo data show that formation of the cartilage rod during axolotl tail 
regeneration is severely disturbed when impairing Bmp signaling. This might not seem 
surprising as “bone” morphogenetic proteins seem likely to have an effect on cells of the 
chondrogenic lineage, but again, our data also show a phenotype in muscle cells and an 
overall disturbed fin morphology in noggin-Fc- or drug-treated animals. Once more this 
points to a more general effect, as it seems unlikely that such a broad defect can occur by 
merely inhibiting muscle cell dedifferentiation. On the other hand, rather surprisingly, spinal 
cord outgrowth seems to be affected at a much lower level even when injecting the noggin-Fc 
molecule directly into the regenerating spinal cord. There also seems to be a difference when 
inhibiting the Bmp signaling versus inhibiting hedgehog signaling, as the noggin-Fc / 
dorsomorphin phenotype looks profoundly different than the much more severe inhibition of 
regeneration seen when inhibiting hedgehog signaling, for example by the drug cyclopamine 
(Schnapp et al., 2005). To what extent and what tissues exactly inhibition of Bmp signaling 
does affect during urodele tail regeneration, of course remains to be studied and will for sure 
be addressed in other experiments in the near future. 
 
F. Perspective 
 
Bmp 4/7 is the first pure biological molecule that has been shown to cause S phase re-entry in 
A1 myotubes. Given that our future experiments prove that Bmp 4/7 is SPRF, we would have 
not only identified a key player in the dedifferentiation of urodele muscle cells but also 
showed that it acts beyond S phase re-entry and even muscle cell dedifferentiation but has a 
role in regeneration also in vivo.  
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Having identified the molecule responsible for the cell cycle re-entry in urodele muscle cells, 
we could now ask the question what makes mammalian cells refractory. For example are they 
missing a crucial receptor or is signaling in the mammalian cells impaired? With noggin as an 
extracellular inhibitor and Dorsomorphin as an intracellular inhibitor, we would in addition 
have two good tools to help studying this pathway. If mammalian cells could be shown to 
miss the receptor responsible for dedifferentiation, could ectopic expression of this receptor 
induce mammalian cells to dedifferentiate? What effect would a constitutively active receptor 
have in amphibian and in mammalian cells?  
Other interesting questions are for example what causes the G2 block in A1 myotubes. Is 
another factor required in vivo to push the dedifferentiating cells beyond this block? 
Moreover, what is the connection between the necessity for muscle fiber clipping in the 
process of regeneration as shown by Karen Echeverri (Echeverri and Tanaka, 2002), and our 
activity? What are the signals created by local tissue injury and how do they act together to 
elicit the full regenerative response? Do any of those signals induce cells to produce Bmp 
4/7? Do they make cells responsive to Bmp signaling? 
The possible identification of Bmp 4/7 as an important molecule in regeneration would 
provide researchers with a good starting point to address many other questions of 
regeneration. It will hopefully prove to be very helpful in answering many of those. 
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IV.  Materials & Methods 
 
If not mentioned otherwise, all standard laboratory techniques were performed 
according to (Sambrook, 2001). 
 
A. A1 Cell Culture and Myotube Assay 
 
1. Cell Culture Solutions 
 
a) APBS (Amphibian PBS) 
 100 ml PBS (Gibco) were mixed with 25 ml sterile ddH2O and stored at RT. 
 
b) Trypsin-EDTA 
Aliquots of a 10x Trypsin-EDTA solution (Gibco 15400-054; stored at -20°C) were thawed 
in a 37°C water bath and diluted into 36 ml APBS and stored at 4°C. 
 
c) Gelatin 
7.5 g gelatin (Sigma G-2500; Type A, from porcine skin, 300 bloom) were dissolved in 1000 
ml water at 65°C for 15 to 30 min and sterile filtered through a 0.22 µm steri-top. Aliquots 
were stored at 4°C. 
 
d) FBS (Fetal Bovine Serum) 
FBS (Perbio CH30160.03) was thawed in a water bath at 37°C and heat-inactivated at 56°C 
for 30 min. Aliquots of 40 ml, 4ml and 200 µl were frozen and stored at -30°C.  
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e) Insulin 
250 mg insulin (Sigma I-5500) were dissolved in 25 ml 0.1 M HCl on a magnetic stirrer and 
225 ml APBS added. The final clear solution was sterile filtered, aliquotted into 4 ml aliquots 
and stored at -20°C. 
 
f) Glutamine 
Frozen glutamine-solution (Gibco 25030-024) was thawed in a 37°C water bath and 4 ml 
aliquots stored at -20°C. 
 
g) Penicillin-Streptomycin 
Frozen Penicillin/Streptomycin-solution (Gibco 15140-122) was thawed in a 37°C water bath 
and 4 ml aliquots stored at -20°C. 
 
h) High Serum AMEM (10% FBS) 
250 ml MEM, w/o L-Glutamine (Gibco 21090-022)  
100 ml ddH2O 
4 ml insulin 
4 ml penicillin-streptomycin 
4 ml glutamine 
40 ml FBS 
 
i) Low Serum AMEM (0.5% FBS) 
230 ml MEM, w/o L-Glutamine (Gibco 21090-022)  
20 ml High Serum AMEM  
140 ml ddH2O 
4 ml insulin 
4 ml penicillin-streptomycin 
4 ml glutamine 
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j) Serum free AMEM 
250 ml MEM, w/o L-Glutamine (Gibco 21090-022) 
140 ml ddH2O 
4 ml insulin 
4 ml penicillin-streptomycin 
4 ml glutamine 
 
k) Serum free BSA AMEM 
250 ml MEM, w/o L-Glutamine (Gibco 21090-022) 
140 ml ddH2O 
4 ml insulin 
4 ml penicillin-streptomycin 
4 ml glutamine 
40 mg BSA (Bovine albumin Fraction V, SERVA 11926) 
 
l) Freezing media 
18 ml High Serum AMEM were mixed with 2 ml DMSO (Sigma), aliquotted and stored at -
20°C. 
 
m) Fibronectin 
Fibronectin, a kind gift from Dr. Carsten Werner of the Max Bergmann Center of 
Biomaterials Dresden, was prepared by Juliane Drichel according to Brew and Ingram (Brew, 
1994) 
 
n) BrdU (5-bromo-2’deoxyuridine) 
BrdU (Sigma B-9285) was dissolved in ddH2O to a final concentration of 10 mg/ml, 
aliquotted and stored at -20°C. 
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o) Soy Bean Trypsin Inhibitor 
Soybean trypsin inhibitor (SERVA 37328) was dissolved in SF-AMEM to a concentration of 
10 mg/ml, aliquotted and stored at -80°C. 
 
p) 100- and 35 µm filter 
Sheets of CellMicroSieves (Promochem) with a pore size of 100 µm and 35 µm were cut in a 
cell culture hood into 3 x 3 cm pieces and sterilized under UV-light in the cell culture hood 
overnight. 
 
2. Solutions for fixation and staining of myotube assay 
 
a) 6% PFA 
24 g paraformaldehyde (Riedel-de Haen 16005) were dissolved in 360 ml ddH2O and 8 drops 
of 5 M NaOH in a 60°C water bath with occasional swirling. After all of the PFA was 
dissolved the solution was cooled down on ice, 40ml 10x PBS were added, the pH adjusted to 
8 with 37% HCl and aliquots stored at -20°C. 
 
b) 20% NaN3  
20 g NaN3 (Merck 1.06688) was dissolved in 100 ml ddH2O, sterile filtered and stored at 
4°C. 
 
c) 1x PBS, 0.01% BSA, 0.1% NaN3 (“0.01%BSA-PBS”) 
100 mg BSA (Bovine albumin fraction V, SERVA 11926) and 5 ml 20% NaN3 were 
dissolved in 1 l PBS, sterile-filtered and stored at 4°C. 
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d) 1x TBS, 0.1% Tween-20 (TBS-Tween) 
1g Tween-20 
100 ml 10xTBS 
900 ml ddH2O 
 
e) Goat serum 
Goat Serum (Gibco 16210-072) was thawed in a water bath at 37°C, heat-inactivated at 56°C 
for 30 min, aliquotted and stored at -20°C. 
 
f) 10% goat serum in 1x TBS, 0.1% NaN3 (“10% GS”) 
20 ml Goat Serum 
180 ml 1x TBS 
1ml 20% NaN3 
The solution was sterile filtered and stored at 4°C.  
 
g) Hoechst 33342 (1mg/ml) 
Hoechst 33342 (Bisbenzimide H 33342, Sigma B-2261) was dissolved in ddH2O at 
1 mg/ml and kept in the dark at 4°C. 
 
h) Monoclonal mouse anti-Bromodeoxyuridine (BrdU) antibody 
Monoclonal mouse anti-Bromodeoxyuridine antibody (clone BU20a) was obtained from the 
Antibody Facility of the Max Planck Institute of Molecular Cell Biology and Genetics 
Dresden in purified form. 
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i) Monoclonal mouse anti-muscle-specific myosin heavy chain 
antibody 
Monoclonal mouse anti-muscle-specific myosin heavy chain IgG1 antibody (clone 4A1025) 
was obtained from the Antibody Facility of the Max Planck Institute of Molecular Cell 
Biology and Genetics Dresden in purified form. 
 
j) Fluorescein-succinimydyl ester 
5-(and-6)-carboxyfluorescein, succinimidyl ester (5(6)-FAM, SE) “mixed isomers” 
(Molecular Probes C-1311) was freshly dissolved in DMSO at 1.5 mg/ml just before use and 
stored at -20°C. 
 
k) Tetramethylrhodamine-succinimidyl ester 
5-(and-6)-carboxytetramethylrhodamine, succinimidyl ester (5(6)-TAMRA, SE) “mixed 
isomers” (Molecular Probes C-1171) was freshly dissolved in DMSO at 1.5 mg/ml just 
before use and stored at -20°C. 
 
3. Growth and maintenance of newt A1 cells, myotube assay 
 
a) Preparation of directly labeled antibodies 
Purified antibody was concentrated to 1 – 3 mg/ml and a NAP-10 column equilibrated with 
0.2 M borate buffer (pH 8.0). 700 µl to 1 ml antibody solution was then desalted on the NAP-
10 column and eluted into 1.5 ml 0.2 M Borate Buffer (pH 8.0). Antibodies were then labeled 
with 25 µl of Tetramethylrhodamine-succinimidyl ester or Fluoresceinsuccinimidyl ester per 
500 µl antibodies for 4 h on a rotation shaker at RT. The labeling reaction was quenched with 
30 µl 100 mM Glycine (pH 7.0) per  
525 µl mix, each 555 µl then desalted over NAP-10 columns into 1.5 ml 1X PBS/0.1% 
NaN3. For long-term storage 1/10th volume of 1% BSA /1X PBS was added and each mix 
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diluted 1: 1 in 100% glycerol. Antibody solutions were stored at -20° and working dilutions 
assessed in myotube assays. 
 
b) Thawing of frozen A1 cells 
A 164 cm2 cell culture flask was gelatin-coated and a cryotube of A1 cells thawed in a water 
bath at 25°C. Immediately after thawing cells were transferred into a 15 ml Falcon tube, 
mixed with 6 ml fresh High Serum AMEM and spun down for 3 min at 1000 x g. The 
supernatant was aspirated and the cells resuspended in 2 ml High Serum AMEM. Cells were 
diluted into the gelatin-coated 164 cm2 flask containing 25 ml High Serum AMEM and 
further passaged as described below. 
 
c) Freezing Of A1 Cells 
High Serum AMEM from a flask of confluent A1 cells was aspirated; the flask washed with 
7 ml APBS and the APBS aspirated. The cells were then incubated with 6 ml TE until most 
cells detached and trypsinization was stopped with 3 ml High Serum AMEM. Cells were 
spun down in a 15 ml Falcon tube for 3 min at 1000 g and the supernatant aspirated. After 
resuspending gently in 1 ml freezing media, cells were immediately transferred into a 
cryotube, frozen at -80°C and the whole tube transferred into liquid nitrogen the next day. 
 
d) Passage of A1 cells and re-plating for myotube induction 
Newt A1 cells were passaged once per week by splitting one confluent 175 cm2 flask into 
three. The two remaining flasks were re-plated each onto one 10 cm dish to prepare cells for 
myotube induction. To limit the size of forming myotubes a 3cm wide grid was scratched 
into the 10 cm dishes with a scalpel. The bottom of 3 new flasks and the scratched 10cm 
plates were coated with gelatin by serial transfer of 10 ml gelatin. 
Media from three flasks was aspirated; the flasks washed with 7 ml APBS and the APBS 
aspirated. Flasks were then incubated with 7 ml TE until most of the cells detached (usually 
between 2 and 5 minutes) and trypsinization was stopped by addition of 3 ml High Serum 
AMEM. Cells were then spun down in 15 ml Falcon tubes for 3 min at 1000 g and the 
supernatant aspirated. The three gelatin-coated flasks were filled with 25 ml and the two 10 
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cm dishes with 10 ml High Serum AMEM. One cell pellet was resuspended in 6 ml High 
Serum AMEM and 2 ml transferred into each flask. The two remaining pellets were 
resuspended in 4 ml High Serum AMEM and 2 ml added to each 10 cm dish. 
 
e) Initiation of myogenesis in newt A1 cells 
Myogenesis is induced by lowering the serum concentration in the medium from 10% to 
0.5%. 
24 hours after passaging of A1 cells into 10cm dishes, the media from the 10 cm dishes was 
aspirated, cells were washed with 5ml APBS, APBS was aspirated and 10 ml Low Serum 
AMEM was added. 
 
f) Myotube purification 
For myotube assays, purified newt A1 myotubes were re-plated on fibronectin-coated 96 well 
plates (Corning 3595). To obtain roughly 80 myotubes per well, myotubes from two 
scratched 10 cm dishes were purified and distributed over one plate. 96 well plates were 
coated with 30 µl of 150 µl fibronectin diluted into 3.5 ml SF-AMEM (final concentration of 
10 µg/ml) and incubated for either 2 hours at RT or overnight at 4°C. Because after 4 days in 
Low Serum AMEM more than 90% of A1 cells have fused and formed multinucleated cells 
(Lo et al., 1993), purification of myotubes was performed roughly 4.75 days after starting the 
Low Serum AMEM incubation.  To size-separate cell suspensions two 100 µm and two 35 
µm filters were glued with hot tweezers on 25 ml plastic tubes (NUNC 364246). Low Serum 
AMEM was aspirated from two scratched 10cm plates, the cells washed with 5 ml APBS, the 
APBS aspirated and the cells then briefly trypsinized with 2 ml TE. As soon as first clumps 
of cells detached, the trypsin was inhibited by addition of 6ml low serum AMEM and 
subsequently cells were gently resuspended by pipetting up and down five times. To remove 
cell clumps, each suspension was dripped through one 100 µm filter and the filter washed 
with 4 ml low serum AMEM.  
To then separate myotubes from the abundant myoblasts the flowthrough from one 100 µm 
filter was dripped through a 35 µm filter that retains the larger myotubes. Myotubes on the 
filter were quickly washed with 4 ml of Low Serum AMEM and the filter afterwards 
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transferred into a 6 cm dish containing 4 ml Low Serum AMEM. The filter was then quickly 
washed with 4 ml of Low Serum AMEM. The same workflow was then repeated with the 
second flowthrough, with the second set of filters but into the same 6 cm dish. The combined 
purified myotubes were then transferred into a 25 ml tube and filled up to 16 ml with low 
serum AMEM. The fibronectin solution was then aspirated from the 96 well plate and 150 µl 
of purified myotubes added to each well. 
 
Note: 
In serum-free myotube purifications all steps were performed using SF-BSA AMEM instead 
of Low Serum AMEM. Trypsin was inhibited with 200 µl soybean trypsin inhibitor prior to 
the addition of 6ml SF-BSA AMEM. 
 
g) Sample addition to myotube S-phase re-entry assay 
Samples were added in triplicates roughly 24 hours after myotube purification to give 
myotubes time to attach to the plate. 
After removal of 100 µl from each well, first low serum AMEM and then sample ranging 
from 5 to 100 µl was added to a final volume of 150 µl in each well. Each plate contained a 
triplicate positive control (70µl LS-AMEM, 30µl FBS) and a triplicate negative control (100 
µl LS-AMEM). 
 
Note: Serum free myotube assays use SF-BSA AMEM instead of low serum AMEM. 
 
h) BrdU addition to myotube S-phase re-entry assay 
3.5 days after sample addition myotubes were incubated for 12 to 16 hours with BrdU. A 10 
mg/ml aliquot of BrdU was thawed in a water bath at 37°C and 40 µl mixed into 2 ml SF-
AMEM. 10 µl of the mixture was added to each well (final concentration in well 13 µg/ml). 
 
i) Myotube assay fixation 
5ml 6% PFA were thawed at 37°C and immediately mixed 1:1 with PBS (final 3% PFA). To 
fix myotubes 50 µl 3% PFA were added to one column of the 96 well plate using a 8-channel 
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multipipette, After 15 s this column was aspirated quickly with a multiwell plate 
washer/dispenser manifold (Sigma M-2656) and the column was washed twice with 100 µl 
0.01% BSA-PBS. Cells were then methanol-fixed by addition of 75 µl ice-cold methanol for 
5 min. 
 
j) Myotube assay staining 
Methanol was aspirated from the 96 well plate and the myotubes rehydrated for 5 min in 75 
µl TBS-Tween. Cells were then incubated in 75 µl 2 M HCl for 12 min to denature DNA in 
the nucleus and subsequently washed 4 times with 75 µl TBS-Tween. FITC-labeled mouse 
anti myosin heavy chain antibody and rhodamine labeled mouse anti BrdU antibody were 
diluted 1:200 into 4 ml 10% GS and 35 µl of the mix applied to each well. Cells were stained 
at 4°C in the dark for 24 h up to one week. Cells were then washed 4 times with 75 µl TBS-
Tween. For staining of nuclear DNA 7 µl of Hoechst stock was diluted in 3.5 ml TBS-Tween 
and all wells incubated for 5 min in 30 µl. Wells were then washed 3 times with 75 µl TBS-
Tween and stored in the dark in 75 µl methanol at 4°. 
 
k) Myotube assay counting 
Assays were counted on an Axioplan 2 imaging microscope (ZEISS) with a 10X objective in 
a dark room using a FITC/TRITC dual band filter set (CHROMA 51004v2). Myotubes were 
identified by green cytoplasmic staining of muscle-specific myosin heavy chain (FITC). 
Positive nuclei were recognized by red nuclear staining of BrdU (rhodamine). 
The percentage of stimulated myotubes in a well was counted by counting the myotubes 
(green) with stimulated nuclei (red) over the total number of myotubes. Each cluster of 
myotube nuclei was counted separately. A myotube was counted positive if at least 2 nuclei 
in a cluster were positive. If necessary, nuclear Hoechst staining was used to identify 
myotube nuclei with filter set 01 (ZEISS). For statistical analysis triplicates were then 
averaged. 
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B. Protein biochemistry 
 
1. Analytical SDS-PAGE 
 
a) General 
Analytical SDS-PAGE was performed either with Tris-Glycine gels (ABIMED, TG42015) 
using Tris-Glycine SDS Running Buffer or with NuPAGE Novex Bis-Tris gels (Invitrogen) 
using NuPAGE MOPS SDS Running Buffer (Invitrogen NP-0001). 
 
5X SDS Sample Buffer (without reducing agent): 
400 mM Tris (pH 6.8) 
10% SDS (Serva 20760) 
50% glycerol 
0.1% Bromphenol Blue (Sigma B-5525)  
mixture was heated up to 50°C and sterile-filtered prior to aliquotting and storage at -20°C. 
 
All gels were run at 130 V at room temperature until the dye front reached the end of the gel. 
 
b) Coomassie staining 
see (Sambrook, 2001) 
 
c) Silver staining 
Silver stain fix: 
 600 ml ddH2O 
 300 ml EtOH 
 100 ml glacial acetic acid 
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Reducer: 
 67 ml ddH2O 
 30 ml EtOH 
 3.3 ml 3M sodium acetate 
 100 mg sodium thiosulfate 
 
Silver nitrate solution: 
 100 ml ddH2O 
 100 mg silver nitrate (Merck 1.01512) 
 25 µl 37% formaldehyde 
Developer: 
 160 ml ddH2O 
 40 ml 12.5% sodium carbonate 
 100 µl 37% formaldehyde 
 
Except Silver stain fix, all solutions were prepared fresh directly before use. Chemicals for 
solutions were stored at RT. 
Gels to be stained were washed with water and incubated twice in silver stain fix for 15 min. 
Gels were then incubated in 50 ml Reducer for 20 min, washed three times for 5 minutes with 
ddH2O and incubated in 50 ml Silver Nitrate Solution for 20 min. To visualize bands, gels 
were then quickly rinsed once with ddH2O and twice with developer prior to incubation in 50 
ml developer on a vertical shaker. As soon as bands had reached the desired intensity the 
reaction was stopped by quick addition of 500µl glacial acetic acid. Gels were left in this 
solution for 5 minutes and then washed three times for 5 min with ddH2O.  
 
2. Western Blot 
 
Protein transfer onto nitrocellulose blotting membrane was performed in the Hoefer semi dry 
chamber according to the manufacturer’s instructions. If not mentioned otherwise, the 
membrane was blocked in 5% milk in PBS-Tween (0.1%) and subsequently incubated in 
primary antibody solution (around 50 ng/ml in 5% milk / PBS-Tween (0.1%)) rocking for 45 
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minutes at RT. After washing the membrane 3x in PBS-Tween (0.1%) for 5 minutes each, it 
was incubated in secondary antibody solution (around 500 ng/ml in PBS-Tween (0.1%)) for 
30 minutes rocking at RT. Finally, the membrane was washed 3x in PBS-Tween (0.1%) for 8 
minutes each, signal was enhanced with the Amersham ECL Western Blotting Detection 
Reagents (GE Healthcare, RPN-2209) and detected on Amersham Hyperfilm ECL (GE 
Healthcare, 28-9068) developed in a Kodak X-OMAT 2000 machine. 
3. Desalting 
 
Nap-5 columns (GE Healthcare, 17-0853-02) were washed three times with 1X PBS and 
three times with the desired medium. Up to 500 µl of sample were applied and desalted into 1 
ml medium according to the manufacturer’s instructions. Columns were washed three times 
in 10x PBS and stored at 4°C for re-use. 
 
4. Trichloroacetic acid precipitation for SDS-PAGE 
 
Resuspension Buffer  
1 ml 200 mM Tris base, 20 mM EDTA  
1.2 ml 2X SDS Sample Buffer (from 5X SDS Sample Buffer)  
0.3 ml 1 M DTT (or water for non-reducing conditions)  
 
Protein sample was mixed with an equal volume of 20% (w/v) trichloroacetic acid (TCA, 
final concentration 10%). After incubation for 15 min on ice the sample was spun for 5 min 
at 25 000 x g, the supernatant aspirated and remaining TCA removed after a second spin. The 
pellet was washed with acetone, spun again, the acetone discarded and the pellet dissolved in 
25µl Resuspension Buffer. If the sample was yellow after resuspension, 1 M Tris base was 
added until the sample turned blue. To redissolve the pellet it was incubated at 50°C. To 
denaturate proteins the sample was boiled for 5 min. The sample was then immediately 
diluted in 2x or 5x SDS sample buffer and run on SDS-PAGE. 
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C. Purification of SPRF 
 
1. Purification system 
 
All chromatography steps were performed on a BioCad SPRINT FPLC System (Perseptive 
Biosystems, Inc., Framingham, MA, USA) at room temperature. Absorbance at 280 nm and 
254 nm, conductivity and pH-value were constantly measured by inline flow cells. 
 
2. Materials used across the purification 
 
All buffers used in chromatography were sterile filtered prior to use. 
 
a) 100 mM cation buffer (pH 4.5 and pH 7.5) 
33.3 mM HEPES (Roth 9105.3)  
33.3 mM MES (Calbiochem 475893)  
33.3 mM NaAcetate (Merck 1.06268) 
pH-adjusted with HCl or NaOH 
 
b) 500 mM phosphate buffer (pH 7.0) 
a 1:1 mixture of 1 M di-sodium hydrogen phosphate (Na2HPO4) (Merck 1.06586) and 1 M 
sodium di-hydrogen phosphate (NaH2PO4) (Merck 1.06346). 
 
c) 100 mM anion buffer (pH 6 and pH 9) 
50 mM Tris (Roth 4855.2) 
50 mM Bis-Tris-Propane (Sigma B-6755) 
pH adjusted with HCl or NaOH, respectively 
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d) 20 mM anion buffer (pH 7.0) 
15.7% 100 mM anion buffer (pH 6.0) 
  4.3% 100 mM anion buffer (pH 9.0) 
80.0% ddH2O 
 
e) Carrier-mix (12 ml) 
10 ml 1 mg/ml insulin (see cell culture)  
1 ml 100 mM anion buffer (50 mM Tris, 50 mM Bis-Tris-Propane, pH 9.0) 
0.5 ml ddH2O  
0.5 ml 20 mg/ml aprotinin 
if not directly used shock-frozen and stored at -20°C. 
 
f) ConA Binding Buffer 
20 mM Tris-HCl (pH 7.0) 
0.5 M NaCl, 
1 mM CaCl2 
1 mM MnCl2 
 
g) ConA Elution Buffer 
20 mM Tris-HCl (pH 7.0) 
0.5 M NaCl 
1 mM CaCl2 
1 mM MnCl2 
0.5 M methyl-alpha-D-glucopyranoside 
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h) Lentil lectin Elution Buffer 
20 mM Tris-HCl (pH 7.0) 
0.5 M NaCl 
1 mM CaCl2 
1 mM MnCl2 
0.5 M methyl-alpha-D-mannopyranoside 
 
i) ConA Regeneration Buffer 
20 mM Tris-HCl (pH 8.5) 
1 M NaCl 
1 mM CaCl2 
1 mM MnCl2 
 
j) ConA Storage Buffer 
20mM Tris-HCl (pH 7.0) 
0.5 M NaCl 
20 % EtOH 
1 mM CaCl2 
1 mM MnCl2 
 
k) WGA Binding Buffer 
20 mM Tris-HCl (pH 7.0) 
0.5 M NaCl 
 
 
 
 
 
 
 93 
l) WGA Elution Buffer 
20 mM Tris-HCl (pH 7.0) 
0.5 M NaCl 
1 mM CaCl2 
1 mM MnCl2 
0.5 M N-actyl-D-glucosamine 
 
m) WGA Regeneration Buffer 
20 mM Tris-HCl (pH 8.5) 
1 M NaCl 
 
n) WGA Storage Buffer 
20mM Tris-HCl (pH 7.0) 
0.5 M NaCl 
20 % EtOH 
 
o) pH 11 gel filtration buffer 
20 mM CAPS (pH 11) (Sigma C-6070)  
200 mM NaCl (Merck1.06404) 
 
p) Gel filtration marker 
Gel filtration LMW and HMW calibration kit (APBiotech) was used as markers in gel 
filtration experiments. Markers are blue dextran 2000 (2000 kDa), thyroglobulin (669 kDa), 
ferritin (440 kDa), catalase (232 kDa), aldolase (158 kDa), bovine serum albumin (67 kDa), 
ovalbumin (43 kDa), chymotrypsinogen A (25 kDa) and ribonuclease A (13.7 kDa). 
 
q) PPACK (D-Phe-Pro-Arg-chloromethylketone, HCl) 
Aliquots of 10mM PPACK (Calbiochem 520222) in 10mM HCl, stored at -80°C. 
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r) Protease inhibitor cocktail (PI’s) 
1000x solution of protease inhibitors chymostatin (6 mg/ml), leupeptin (0.5 mg/ml), antipain-
HCl (10 mg/ml), aprotinin (2 mg/ml), pepstatin (0.7 mg/ml) and APMSF (10 mg/ml)  (all 
from Sigma) in DMSO, stored at -20°C.  
 
3. Columns used across the purification 
 
Chromatography 
Mode 
Column Supplier Flow rate 
Cation Exchange HiTrap CMFF (5ml) APBiotech 5 ml/min 
 HiPrep CMFF (20ml) APBiotech 5 ml/min 
Hydrophobic 
Interaction 
HiTrap Butyl-FF (5ml) APBiotech 5 ml/min 
 HiPrep Butyl-FF (20ml) APBiotech 5 ml/min 
Affinity HiTrap Heparin (5ml) APBiotech 5 ml/min 
 HiTrap Lentil Lectin 
(1ml) 
APBiotech 0.5 ml/min 
 HiTrap WGA (1ml) APBiotech 0.5 ml/min 
 ConA (1ml) Sigma (C-9017) self-
poured 
0.5 ml/min 
Gel filtration Siperdex-200 HR 10/30 
(24 ml) 
APBiotech 0.25 ml/min 
Table IV-1: Columns used across the purification, suppliers and flow rate used. 
 
4. Calculation of protein concentration 
 
Protein concentrations in purification fractions were determined by integration of absorbance 
at 280 nm. (A280 of 1 corresponds to 1 mg/ml). The data file for each purification run was 
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exported into an excel spreadsheet (1 data-point per second), and baseline shift as well as 
flow cell path length of the UV/VIS detector (3 mm) were accounted for. 
 
5. Thrombin inhibition assay 
 
A kinetic thrombin assay was performed to check for complete inhibition of thrombin by 
PPACK. Chromozym TH (Roche 206849), a chromogenic thrombin substrate was dissolved 
in ddH2O at 1 mg/ml and 1.5 ml aliquots were stored at -80°C. Aliquots of frozen 
Chromozym TH were thawed, diluted 1:10 into thrombin assay buffer (1X TBS, 0.01% BSA, 
0.1% NaN3) and stored at 4°C. Prior to use the buffer was warmed up to RT. 10 µl of each 
sample were assayed in triplicates in flat 96-well-plates. 200 µl of thrombin assay buffer 
(containing Chromozym TH) were added to each well and the plate immediately analyzed in 
a plate reader. Activity of thrombin was calculated as the slope of absorption at 405 nm 
(ΔOD 405 nm/min) over 5 minutes by measuring absorption every 20 s. As a control 10 µl of 
a crude bovine thrombin dilution series (1:100, 1:200, 1:400) were assayed. 
 
6. Mass spectrometry analysis 
 
Mass spectrometry analysis on purified fractions was performed in the MPI-CBG Mass 
Spectrometry Facility by Natalie Wielsch. Proteins were excised from a Coomassie-stained 
gel and trypsin-digested according to (Shevchenko et al., 1996). Tryptic peptides were 
extracted from the gel matrix by 5% formic acid and acetonitrile extraction. Extracts were 
then dried in a vacuum centrifuge and re-dissolved in 10 µl 0.04% trifluoroacetic acid (TFA). 
Peptides were analyzed by LC MS/MS on a LTQ ion-trap mass spectrometer according to 
(Mayya et al., 2005). Tandem mass spectra were searched against all bovine proteins in the 
NCBI database using MASCOT software, version 2.1 (Matrix Science, London, UK) 
installed on a local server. 
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D. Testing and overexpression of candidate proteins 
 
1. Overexpressing proteins in the Freestyle TM 293 Expression 
system (Invitrogen K9000-01), concentration on 
VIVASPIN 20 and purification on protein A column 
 
a) Maintenance of 293 cells 
Cells were frozen, thawed and passaged according to the manufacturer’s instructions by 
Régis Lemaitre of the Protein Expression Facility at MPI-CBG. 
 
b) Transfection of 293 cells 
DNA to be transfected was dissolved at 15 µg / ml in pre-warmed (37°C) Freestyle 293 
media (Invitrogen 12338-026) and 3.3 µg PEI transfection reagent (PolyEthyleneImine, 
Polysciences, 23966) were added per µg of DNA. The solution was then thoroughly vortexed 
and left to incubate at RT for 30 minutes. 293 cells (106 cells / ml) were transferred into fresh 
media and 1 ml of DNA mixture was added to 50 ml cell suspension (106 cells / ml). 
Transfected cells were grown at 37°C. 
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c) Expression vector 
 
Figure IV-1: Expression vector for transfection into 293 cells. 
Candidate DNA was cloned in frame into the multiple cloning site (MCS) and then overexpressed in 293 cells. 
This led to the expression of the candidate fused N-terminally to the signal sequence of the CD33 protein and C-
terminally to a cleavable Fc-tag behind a 3C protease sire. Vector was also used for injection into axolotl larvae 
spinal cord with or without human noggin DNA cloned into the MCS. 
 
d) Harvesting and concentration of 293-cell supernatant  
293 cells were spun in a tabletop centrifuge for 5 min at 2000 g, 4°C, the supernatant 
decanted and centrifuged again for 5 min at 2000 g, 4°C to remove cells. Cell supernatant 
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was then sterile-filtered and if necessary concentrated on previously saturated VIVASPIN-20 
vials with MWCO of 5 kDa according to the manufacturer’s instructions. 
Supernatants were then again sterile-filtered, shock-frozen in liquid nitrogen and stored at -
80°C or processed further. 
 
e) Saturation of VIVASPIN 20 vials 
VIVASPIN-20 vials with a MWCO of 5 kDa (VWR, 512-3784) were incubated with 20 ml 
of a 50 µg/ml BSA/PBS solution for 20 minutes and spun in a swinging-bucket rotor for 5 
min at 2500 g, 4°C in a tabletop centrifuge to saturate the VIVASPIN membrane. Remaining 
BSA solution was removed and the membrane washed with PBS. 
 
f) Candidate purification on protein A column 
1 ml Protein A column was connected to a pump and placed at 4°C. After equilibration of the 
column with 10 CV 293 medium supplemented with 50 mM Hepes (pH 7.4). Sterile-filtered 
supernatants from the 293 cell overexpression system were also brought to 50 mM Hepes 
(pH 7.4) and then loaded onto the column. Column was then washed with 10 CV 293 
medium, 50 mM Hepes (pH 7.4).  3C protease was diluted to 50 µg/ml in 3C cleavage buffer 
and 1ml of this slowly (over period of 1 min) injected onto the column. After incubation for 
90 min, cleaved proteins were eluted with 5 – 10 CV 3C cleavage buffer and columns 
cleaned with 10 CV 0.1M glycine, 0.5M NaCl (pH2).  
 
3C cleavage buffer:  
 50 mM Hepes (pH 7.4) 
 150 mM NaCl 
 1 mM EDTA 
 1 mM DTT 
 0.1 % Tween-20 
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2. Thrombin activation of candidate proteins 
 
a) Materials 
F3: A thrombin preparation purified from of crude bovine thrombin by Dr. Drechsel 
on a strong cation exchange column and eluted with 1.5 M NaCl. 
Spike: GST-ROK-RBD construct, the GST-tagged Rho-binding domain from the 
Rho-associated, coiled-coil containing protein kinase 2 at 1.1 mg/ml, with a thrombin 
cleavage site between the GST-tag and the kinase. 
FBS: see materials A1 cell culture 
PPACK and PI’s: see materials used across the purification 
 
b) Experimental set up 
Irrespective of their concentration, 12.5 µl candidate protein was mixed with 2 µl F3 or PBS 
containing 14 % serum to obtain final 1% serum. Samples were then split for analysis on gels 
and on myotubes, the gel samples then supplemented with 20 % spike containing 1% FBS. 
Samples were then incubated at RT, 750 rpm, O/N. The next day thrombin activity was 
inhibited by 2 µl PPACK and PI cocktail for 5 min on ice in the samples for the myotube 
assay, the samples for the gel were boiled for 10 min in 1x SDS sample buffer and stored at -
20°C. Myotube assay samples were stored at 4°C for up to 1 day before assaying them on A1 
myotubes at final 1 µg/ml candidate protein concentration. 
 
3. Testing of Bmp proteins 
 
Recombinant human bmp proteins and recombinant human Noggin-Fc chimera were 
obtained from R&D Systems.  Bmp 4 (314-BP-010), Bmp 7 (354-BP-010), Bmp 4/7 (3727-
BP-010) and Noggin-Fc (3344-NG-050) were reconstituted according to the manufacturer’s 
instructions, aliquotted, shock-frozen and stored at -80°C. For assaying on A1 myotubes, 
prior to addition to the cells, all samples containing bmp proteins or noggin-Fc were pre-
mixed and incubated for 1 hour at RT.  
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E. In vivo experiments 
 
1. Animal care 
 
Axolotl larvae were kept in Dresden tap water in the in-house facility at 18°C. They were fed 
daily with artemia and taken care of by Heino Andreas.  
 
2. Noggin-Fc injection into spinal cord 
 
Tails of 1.5 to 2.5 cm axolotl larvae were amputated and 0.5 mg /ml noggin-Fc expression 
construct or empty control vector injected into the spinal cord together with fluorescent 
reporter plasmid and FasrGreen Tracker dye to visualize injection. Animals were kept at RT 
and re-amputated after three days through the region of enhanced transgene expression as 
visualized by expression of the fluorescent reporter construct. Regeneration was followed for 
up to 19 days on a Zeiss Axiovert 200M or Zeiss Axio Imager Z.1 inverted microscope with 
a 10x objective. Tails were amputated, fixed and immunostained as described below. 
Expression construct see Figure IV-1. 
 
3. Dorsomorphin experiments 
 
Tails of 2 to 3 cm axolotl larvae were amputated and put into 10 µM Dorsomorphin (Merck, 
171261) or DMSO in tap water and kept in a 6-well dish in the dark at RT. Regeneration was 
followed for up to 10 days on a Zeiss Axio Imager Z.1 inverted microscope with a 10x 
objective. Tails were amputated, fixed and immunostained as described below. 
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4. Whole mount immunostaining 
 
Immediately after amputation tissues were fixed in 4% PFA in PBS for 3 hours to O/N at 
4°C. They were then washed two times for at least 30 min in PBS and two times for at least 
30 min in TBS-Trition-X-100 (0.3 %). If cartilage staining was desired, tissues were 
incubated in 0.15 mg/ml AlcianBlue in 60% EtOH, 40% acetic acid for 1 hour at 37°C, 
washed for 1 h in 60% EtOH, 40% acetic acid and gradually rehydrated (90%, 70% EtOH in 
PBS, 50%, 20%, 2x 0% EtOH in TBS-Triton-X-100, all 20 min each). Tissues were then 
blocked for 1 hour in blocking buffer (TBS-Triton-X-100 (0.3%), 10% goat serum) O/N at 
4°C. Next day, tissues were incubated with primary antibody (usually 1:200 in blocking 
buffer) for 50 hours. Samples were then washed 4x with TBS-Triton-X-100 (0.3%) for 15 
min each and incubated with secondary antibody (usually 1:200 in TBS-Triton-X-100) at 4°C 
O/N. Next day, tissues were washed 4 times, stretched over the day in TBS-Triton-X-100 
before being incubated with 1 µg/ml Hoechst 33342 (see Materials A1 cell culture) In TBS-
Triton-X-100 at 4°C O/N. Finally, tissues were washed 6x 15 minutes in TBS-Triton-X-100, 
30 min in 25% glycerol in TBS-Triton-X-100 and stored in 50% glycerol in TBS-Triton-X-
100 at 4°C. or analyzed on a Zeiss Axio Imager Z.1 inverted microscope with a 10x 
objective. 
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V.  Abbreviations 
 
Apart from standard SI units and prefixes, the following abbreviations were used in this 
thesis: 
 
3C protease Human rhinovirus 3C protease 
AMEM Amphibian MEM 
AMPK Adenosinmonophosphate-activated protein kinase 
APBS Amphibian PBS 
AS Ammonium sulfate 
Bmp Bone morphogenetic protein 
BrdU 5-bromo-2’-deoxyuridine 
BSA Bovine serum albumin 
CAPS 3-(cyclohexylamino)-1-propanesulfonic acid 
cBT Crude bovine thrombin 
CDK Cyclin dependent kinase 
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CMFF Cephyl-methylose fast flow 
ConA Concanavalin A 
CV Column volume 
ddH2O Bi-distilled water 
DIC Differential interference contrast microscopy 
DNA Deoxyribonucleic acid 
dpa Days post amputation 
DTT Dithiothreitol  
ED50 Median effective dose 
EDTA Ethylenediaminetetraacetic acid 
EST Expressed sequence tag 
EtOH Ethanol 
FBS Fetal bovine serum 
Fc Fragment, crystallizable 
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FITC Fluorescein isothiocyanate 
FT Flowthrough 
g g-force 
GF Gel filtration 
GFP Green fluorescent protein 
GST Glutathione S transferase 
HEPES N-(2-hydroxyethyl)piperazine-N’- (2-ethanesulfonic acid) 
HIC Hydrophobic interaction chromatography 
INK Inhibitor of cyclin-dependent kinase 
kDa Kilo Dalton 
LC MS/MS Liquid chromatography mass spectrometry 
LS Low serum 
M Molar (also used in combination with prefixes, e.g. µM) 
MEM Minimum essential medium 
mHC Myosin heavy chain 
MOPS 3-(N-morpholino)propanesulfonic acid 
mRNA Messenger ribonucleic acid 
MS Mass spectrometry 
MW Molecular weight 
MWCO Molecular weight cutoff 
n.a. Not applicable 
n.d. Not determined 
NaAcetate Sodium acetate 
NCBI National Center for Biotechnology Information 
O/N Overnight 
PAGE Polacrylamide gel electrophoresis 
PBS Phosphate-buffered saline 
PEC Pigment epithelial cell 
PFA Paraformaldehyde 
pH pH value 
PI Protease inhibitor 
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PNGFase Peptide: N-Glycosidase F 
PPACK D-Phe-Pro-Arg-chloromethylketone, HCl 
ppm Parts per million 
pRb Retinoblastoma protein 
RT Room temperature 
SDS Sodium dodecyl sulfate 
SI International system of units 
SPRF S phase re-entry factor 
SV 40 Simian vacuolating virus 40 
TBS Tris-buffered saline 
TCA Trichloroacetic acid (CCl3COOH) 
TE Trypsin-EDTA 
TFA Trifluoroacetic acid (CF3COOH) 
Tris Tris- (hydroxymethyl)-aminomethane 
TRITC Tetramethylrhodamine isothiocyanate 
WGA Wheat germ agglutinin 
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